tofacitinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01262118 · Phase 1 · completed
This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.
Next expected readout: January 2027 · NCT06945666 (registry estimate)
Reported efficacy
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)
Result source: NCT01262118
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02675426 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).
Next expected readout: March 2027 · NCT07636057 (registry estimate)
Reported efficacy
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)
Result source: NCT03086343
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | tofacitinib | upadacitinib |
|---|---|---|
| ACR20 | 52.7% vs 31.2%+21.5 vs placeboNCT00856544273 other results
| 63.8% vs 35.7%+28.1 vs placeboNCT0267542649 other results
|
| ACR50 | 33.8% vs 12.7%+21 vs placeboNCT00856544275 other results
| 52.1% vs 28.3%vs MethotrexateNCT0270687341 other results
|
| ACR70 | 25.4% vs 12.1%vs MTXNCT01039688271 other results
| 20.8% vs 5.9%+14.9 vs placeboNCT0267542641 other results
|
| DAS28-CRP remission | 23.0% vs 5.2%+17.8 vs placeboNCT00847613174 other results
| 48.3% vs 18.5%vs MethotrexateNCT0270687322 other results
|
| HAQ-DI, change | -0.5 vs -0.2−0.3 vs placeboNCT00814307233 other results
| -0.6 vs -0.3−0.3 vs placeboNCT0267542632 other results
|
| Modified Sharp score, change | 0.1 vs 0.5−0.3 vs placeboNCT008476137 other results
| 0.1 vs 0.7vs MethotrexateNCT027068734 other results
|
ACR20
- tofacitinib
- 52.7% vs 31.2%+21.5 vs placeboNCT00856544
273 other results
- 51.5% vs 28.3% NCT00853385
- 51.5% vs 25.3% NCT00847613
- 59.8% vs 26.7% NCT00814307
- 41.7% vs 24.4% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 52.5% vs 28.3% NCT00853385
- 61.8% vs 25.3% NCT00847613
- 65.7% vs 26.7% NCT00814307
- 48.1% vs 24.4% NCT00960440
- 52.7% vs 31.2% NCT00856544
- 50.8% vs 25.5% NCT00856544
- 56.3% vs 27.4% NCT00856544
- 60.7% vs 26.4% NCT00853385
- 56.3% vs 27.3% NCT00847613
- 56.9% vs 25.8% NCT00814307
- 54.0% vs 26.1% NCT00856544
- 46.5% vs 21.7% NCT00814307
- 38.6% vs 22.9% NCT00856544
- 41.2% vs 16.0% NCT00853385
- 41.4% vs 16.3% NCT00847613
- 42.4% vs 27.5% NCT00960440
- 29.6% vs 11.8% NCT00814307
- 27.3% vs 10.9% NCT00856544
- 27.7% vs 16.7% NCT00960440
- 58.3% vs 31.2% NCT00856544
- 57.9% vs 25.5% NCT00856544
- 64.7% vs 27.4% NCT00856544
- 58.7% vs 26.4% NCT00853385
- 66.3% vs 27.3% NCT00847613
- 60.7% vs 25.8% NCT00814307
- 64.4% vs 26.1% NCT00856544
- 52.1% vs 21.7% NCT00814307
- 48.5% vs 22.9% NCT00856544
- 45.9% vs 16.0% NCT00853385
- 52.1% vs 16.3% NCT00847613
- 44.4% vs 27.5% NCT00960440
- 39.2% vs 11.8% NCT00814307
- 32.3% vs 10.9% NCT00856544
- 32.8% vs 16.7% NCT00960440
- 71.3% vs 50.5% NCT01039688
- 69.9% vs 51.6% NCT01039688
- 49.5% vs 47.2% NCT00853385
- 72.1% vs 55.4% NCT01039688
- 63.6% vs 42.4% NCT01039688
- 49.3% vs 21.2% NCT01039688
- 49.5% vs 49.3% NCT00853385
- 67.8% vs 51.1% NCT01039688
- 68.8% vs 47.3% NCT01039688
- 64.2% vs 46.7% NCT01039688
- 65.0% vs 45.1% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 76.1% vs 50.5% NCT01039688
- 77.9% vs 51.6% NCT01039688
- 50.5% vs 47.2% NCT00853385
- 73.6% vs 55.4% NCT01039688
- 71.6% vs 42.4% NCT01039688
- 58.3% vs 21.2% NCT01039688
- 49.5% vs 49.3% NCT00853385
- 71.6% vs 51.1% NCT01039688
- 66.2% vs 47.3% NCT01039688
- 66.0% vs 46.7% NCT01039688
- 62.2% vs 45.1% NCT01039688
- 64.2% vs 42.4% NCT01039688
- 73.1% vs 15.4% NCT00687193
- 61.2% vs 23.7% NCT00550446
- 96.3% vs 14.3% NCT00603512
- 56.3% vs 36.2% NCT00413660
- 70.5% vs 29.2% NCT00147498
- 84.9% vs 15.4% NCT00687193
- 72.1% vs 23.7% NCT00550446
- 80.8% vs 14.3% NCT00603512
- 58.1% vs 36.2% NCT00413660
- 76.8% vs 29.2% NCT00147498
- 56.3% vs 36.2% NCT00413660
- 90.7% vs 15.4% NCT00687193
- 71.9% vs 23.7% NCT00550446
- 56% vs 36.2% NCT00413660
- 81.2% vs 29.2% NCT00147498
- 67.9% vs 15.4% NCT00687193
- 45.1% vs 23.7% NCT00550446
- 77.8% vs 14.3% NCT00603512
- 55.9% vs 36.2% NCT00413660
- 37.7% vs 15.4% NCT00687193
- 31.5% vs 23.7% NCT00550446
- 64.3% vs 14.3% NCT00603512
- 47.1% vs 36.2% NCT00413660
- 57.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 69.4% vs 32.4% NCT00550446
- 57.7% vs 47.1% NCT00413660
- 67.3% vs 35.3% NCT00550446
- 53.5% vs 43.1% NCT00413660
- 57.1% vs 23.7% NCT00550446
- 67.3% vs 11.5% NCT00687193
- 63.3% vs 27.1% NCT00550446
- 96.3% vs 21.4% NCT00603512
- 54.9% vs 33.3% NCT00413660
- 50% vs 28.9% NCT00147498
- 63.3% vs 25.4% NCT00550446
- 57.8% vs 37.7% NCT00413660
- 61.5% vs 9.6% NCT00687193
- 40.8% vs 27.1% NCT00550446
- 88.9% vs 10.7% NCT00603512
- 46.5% vs 24.6% NCT00413660
- 63.9% vs 30.8% NCT00147498
- 34.6% vs 5.8% NCT00687193
- 32.6% vs 15.3% NCT00550446
- 63.0% vs 10.7% NCT00603512
- 31.0% vs 15.9% NCT00413660
- 50.8% vs 20% NCT00147498
- 29.6% vs 3.6% NCT00603512
- 27.9% vs 12.3% NCT00147498
- 73.8% vs 47.1% NCT00550446
- 66.2% vs 47.1% NCT00413660
- 73.8% vs 32.4% NCT00550446
- 62.2% vs 47.1% NCT00413660
- 70.5% vs 35.3% NCT00550446
- 64.9% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 86.8% vs 11.5% NCT00687193
- 65.6% vs 27.1% NCT00550446
- 56.8% vs 33.3% NCT00413660
- 55.4% vs 37.7% NCT00413660
- 81.1% vs 9.6% NCT00687193
- 46.0% vs 24.6% NCT00413660
- 66% vs 5.8% NCT00687193
- 70.6% vs 28.9% NCT00147498
- 75.4% vs 30.8% NCT00147498
- 68.1% vs 20% NCT00147498
- 56.5% vs 12.3% NCT00147498
- 62.7% vs 47.1% NCT00413660
- 64.2% vs 47.1% NCT00413660
- 64.2% vs 43.1% NCT00413660
- 56.3% vs 33.3% NCT00413660
- 50% vs 37.7% NCT00413660
- 51.3% vs 24.6% NCT00413660
- 33.8% vs 15.9% NCT00413660
- 80.8% vs 21.4% NCT00603512
- 63.9% vs 25.4% NCT00550446
- 52.5% vs 27.1% NCT00550446
- 76.9% vs 10.7% NCT00603512
- 50.8% vs 15.3% NCT00550446
- 50% vs 10.7% NCT00603512
- 31.1% vs 15.9% NCT00413660
- 38.5% vs 3.6% NCT00603512
- 68.4% vs 47.1% NCT00550446
- 65.3% vs 47.1% NCT00413660
- 71.9% vs 32.4% NCT00550446
- 61.3% vs 47.1% NCT00413660
- 71.9% vs 35.3% NCT00550446
- 62.7% vs 43.1% NCT00413660
- 75.4% vs 23.7% NCT00550446
- 87% vs 11.5% NCT00687193
- 71.9% vs 27.1% NCT00550446
- 64% vs 33.3% NCT00413660
- 66.1% vs 28.9% NCT00147498
- 66.7% vs 25.4% NCT00550446
- 56% vs 37.7% NCT00413660
- 77.8% vs 9.6% NCT00687193
- 63.2% vs 27.1% NCT00550446
- 54.7% vs 24.6% NCT00413660
- 75.4% vs 30.8% NCT00147498
- 53.7% vs 5.8% NCT00687193
- 38.6% vs 15.3% NCT00550446
- 40% vs 15.9% NCT00413660
- 71.0% vs 20% NCT00147498
- 43.5% vs 12.3% NCT00147498
- 58.8% vs 47.1% NCT00550446
- 65.5% vs 47.1% NCT00413660
- 64.7% vs 32.4% NCT00550446
- 67.3% vs 47.1% NCT00413660
- 58.8% vs 35.3% NCT00550446
- 60% vs 43.1% NCT00413660
- 37.3% vs 23.7% NCT00550446
- 62.3% vs 11.5% NCT00687193
- 47.1% vs 27.1% NCT00550446
- 66.7% vs 21.4% NCT00603512
- 54.4% vs 33.3% NCT00413660
- 47.1% vs 25.4% NCT00550446
- 54.4% vs 37.7% NCT00413660
- 47.2% vs 9.6% NCT00687193
- 37.3% vs 27.1% NCT00550446
- 55.6% vs 10.7% NCT00603512
- 45.6% vs 24.6% NCT00413660
- 34% vs 5.8% NCT00687193
- 31.4% vs 15.3% NCT00550446
- 40.7% vs 10.7% NCT00603512
- 36.8% vs 15.9% NCT00413660
- 14.8% vs 3.6% NCT00603512
- 35.1% vs 47.1% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 45.9% vs 32.4% NCT00550446
- 59.2% vs 47.1% NCT00413660
- 51.4% vs 35.3% NCT00550446
- 63.3% vs 43.1% NCT00413660
- 35.2% vs 23.7% NCT00550446
- 37.7% vs 11.5% NCT00687193
- 37.0% vs 27.1% NCT00550446
- 67.9% vs 21.4% NCT00603512
- 50% vs 33.3% NCT00413660
- 38.9% vs 25.4% NCT00550446
- 44.3% vs 37.7% NCT00413660
- 35.8% vs 9.6% NCT00687193
- 22.2% vs 27.1% NCT00550446
- 50% vs 10.7% NCT00603512
- 37.1% vs 24.6% NCT00413660
- 18.9% vs 5.8% NCT00687193
- 16.7% vs 15.3% NCT00550446
- 82.6% vs 65.2% NCT01059864
- 76% vs 76.6% NCT01059864
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 47.1% NCT00413660
- 0% vs 43.1% NCT00413660
- 32.1% vs 10.7% NCT00603512
- 21.4% vs 15.9% NCT00413660
- 28.6% vs 3.6% NCT00603512
- 60% vs 0% NCT00976599
- 68.7% vs 67.6% NCT02092467
- 67.3% vs 63.6% NCT02092467
- 70% vs 68% NCT02092467
- 57.2% vs 56% NCT02092467
- 71% vs 66.6% NCT02092467
- 69.9% vs 66.8% NCT02092467
- 67.4% vs 64.6% NCT02092467
- 65.6% vs 65.4% NCT02092467
- 65.7% vs 63.5% NCT02092467
- 66% vs 62.9% NCT02092467
- 64.1% vs 64.2% NCT02092467
- 64.3% vs 63.5% NCT02092467
- 62.3% vs 61.1% NCT02092467
- 61.6% vs 61.1% NCT02092467
- 62.2% vs 60.9% NCT02092467
- 53.6% vs 54.4% NCT02092467
- 44.9% vs 44% NCT02092467
- 36.8% vs 35.7% NCT02092467
- 29.8% vs 27.6% NCT02092467
- 23.2% vs 20.8% NCT02092467
- 16.7% vs 16% NCT02092467
- 11.2% vs 11.1% NCT02092467
- 5.8% vs 6.1% NCT02092467
- 1.8% vs 2.5% NCT02092467
- 0.3% vs 0.7% NCT02092467
- 69.5% vs 67.6% NCT02092467
- 68.1% vs 63.6% NCT02092467
- 69% vs 68% NCT02092467
- 59.5% vs 56% NCT02092467
- 68.1% vs 66.6% NCT02092467
- 68.9% vs 66.8% NCT02092467
- 66.9% vs 64.6% NCT02092467
- 65.5% vs 65.4% NCT02092467
- 63.3% vs 63.5% NCT02092467
- 63% vs 62.9% NCT02092467
- 61.7% vs 64.2% NCT02092467
- 61% vs 63.5% NCT02092467
- 60.5% vs 61.1% NCT02092467
- 57.9% vs 61.1% NCT02092467
- 58.2% vs 60.9% NCT02092467
- 49.3% vs 54.4% NCT02092467
- 40.3% vs 44% NCT02092467
- 33.3% vs 35.7% NCT02092467
- 27.2% vs 27.6% NCT02092467
- 22% vs 20.8% NCT02092467
- 16.3% vs 16% NCT02092467
- 11.4% vs 11.1% NCT02092467
- 6.9% vs 6.1% NCT02092467
- 2.5% vs 2.5% NCT02092467
- 1% vs 0.7% NCT02092467
- upadacitinib
- 63.8% vs 35.7%+28.1 vs placeboNCT02675426
49 other results
- 64.6% vs 28.4% NCT02706847
- 71.6% vs 31.4% NCT02955212
- 66.2% vs 35.7% NCT02675426
- 56.4% vs 28.4% NCT02706847
- 83.7% vs 42.9% NCT02720523
- 80% vs 42.9% NCT02720523
- 75.5% vs 42.9% NCT02720523
- 67.7% vs 41.2% NCT02706951
- 75.7% vs 54.1% NCT02706873
- 71.2% vs 41.2% NCT02706951
- 77.1% vs 54.1% NCT02706873
- 22.2% vs 8.6% NCT02675426
- 27.4% vs 10.7% NCT02706847
- 25.4% vs 5.9% NCT02955212
- 28.3% vs 8.6% NCT02675426
- 24.8% vs 10.7% NCT02706847
- 24.5% vs 8.2% NCT02720523
- 34% vs 8.2% NCT02720523
- 30.6% vs 8.2% NCT02720523
- 78.9% vs 58.6% NCT02706873
- 78% vs 58.6% NCT02706873
- 85.2% vs 57.1% NCT02706873
- 78.6% vs 57.1% NCT02706873
- 85.5% vs 57.1% NCT02706873
- 81.6% vs 50% NCT02066389
- 76.6% vs 50% NCT02066389
- 70.9% vs 35.2% NCT01960855
- 81.6% vs 50% NCT02066389
- 72.7% vs 35.2% NCT01960855
- 73.5% vs 50% NCT02066389
- 63.5% vs 35.2% NCT01960855
- 64.6% vs 50% NCT02066389
- 55.6% vs 35.2% NCT01960855
- 41.5% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 29.3% vs 42.1% NCT03682705
- 24.4% vs 21.1% NCT03682705
- 30.8% vs 47.4% NCT03682705
- 30.8% vs 36.8% NCT03682705
- 23.1% vs 42.1% NCT03682705
- 12.8% vs 21.1% NCT03682705
- 64.5% vs 47.4% NCT03682705
- 64.5% vs 36.8% NCT03682705
- 51.6% vs 42.1% NCT03682705
- 45.2% vs 21.1% NCT03682705
- 34.1% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 22% vs 42.1% NCT03682705
- 14.6% vs 21.1% NCT03682705
ACR50
- tofacitinib
- 33.8% vs 12.7%+21 vs placeboNCT00856544
275 other results
- 36.7% vs 12.3% NCT00853385
- 32.4% vs 8.4% NCT00847613
- 28.0% vs 8.3% NCT00856544
- 31.1% vs 12.5% NCT00814307
- 27.3% vs 9.6% NCT00856544
- 34.2% vs 6.6% NCT00853385
- 28.8% vs 7.8% NCT00847613
- 26.5% vs 8.4% NCT00960440
- 32.7% vs 20% NCT00847613
- 26.1% vs 5.8% NCT00814307
- 23.1% vs 4.5% NCT00856544
- 17.4% vs 4.2% NCT00814307
- 11.6% vs 1.3% NCT00856544
- 14.9% vs 4.7% NCT00853385
- 16.8% vs 1.3% NCT00847613
- 12.9% vs 6.1% NCT00960440
- 5.8% vs 4.2% NCT00814307
- 5.8% vs 1.3% NCT00856544
- 7.7% vs 1.6% NCT00960440
- 32.7% vs 16% NCT00847613
- 36.6% vs 12.7% NCT00856544
- 34.7% vs 12.3% NCT00853385
- 43.7% vs 8.4% NCT00847613
- 33.3% vs 8.3% NCT00856544
- 36.8% vs 12.5% NCT00814307
- 34.0% vs 9.6% NCT00856544
- 27.6% vs 6.6% NCT00853385
- 36.3% vs 7.8% NCT00847613
- 27.8% vs 8.4% NCT00960440
- 44.0% vs 20% NCT00847613
- 33.9% vs 5.8% NCT00814307
- 29.8% vs 4.5% NCT00856544
- 24.0% vs 4.2% NCT00814307
- 18.1% vs 1.3% NCT00856544
- 16.3% vs 4.7% NCT00853385
- 18.4% vs 1.3% NCT00847613
- 17.3% vs 6.1% NCT00960440
- 12.9% vs 4.2% NCT00814307
- 8.1% vs 1.3% NCT00856544
- 5.5% vs 1.6% NCT00960440
- 41.1% vs 16% NCT00847613
- 46.6% vs 26.6% NCT01039688
- 40.1% vs 20.1% NCT01039688
- 35.7% vs 29.1% NCT00853385
- 49.9% vs 35.3% NCT01039688
- 32.6% vs 11.4% NCT01039688
- 18.0% vs 3.8% NCT01039688
- 36.7% vs 33.7% NCT00853385
- 49.9% vs 33.7% NCT01039688
- 50.7% vs 33.1% NCT01039688
- 48.0% vs 30.4% NCT01039688
- 49.0% vs 30.4% NCT01039688
- 49.3% vs 28.3% NCT01039688
- 56.4% vs 26.6% NCT01039688
- 50% vs 20.1% NCT01039688
- 37.2% vs 29.1% NCT00853385
- 56.9% vs 35.3% NCT01039688
- 40.1% vs 11.4% NCT01039688
- 28.0% vs 3.8% NCT01039688
- 35.7% vs 33.7% NCT00853385
- 55.6% vs 33.7% NCT01039688
- 54.3% vs 33.1% NCT01039688
- 51.8% vs 30.4% NCT01039688
- 50.5% vs 30.4% NCT01039688
- 49.2% vs 28.3% NCT01039688
- 36.7% vs 17.6% NCT00550446
- 39.4% vs 31.4% NCT00413660
- 32.7% vs 17.6% NCT00550446
- 38% vs 31.4% NCT00413660
- 34.7% vs 20.6% NCT00550446
- 38% vs 21.6% NCT00413660
- 46.2% vs 7.7% NCT00687193
- 38.8% vs 10.2% NCT00550446
- 81.5% vs 14.3% NCT00603512
- 36.6% vs 17.4% NCT00413660
- 34.7% vs 6.8% NCT00550446
- 44.2% vs 1.9% NCT00687193
- 24.5% vs 8.5% NCT00550446
- 70.4% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 17.9% vs 13.3% NCT00147498
- 14.3% vs 6.8% NCT00550446
- 31.0% vs 8.7% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 28.8% vs 1.9% NCT00687193
- 10.2% vs 5.1% NCT00550446
- 29.6% vs 3.6% NCT00603512
- 11.3% vs 2.9% NCT00413660
- 32.8% vs 6.2% NCT00147498
- 11.5% vs 0% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 25.9% vs 0% NCT00603512
- 5.6% vs 2.9% NCT00413660
- 9.8% vs 3.1% NCT00147498
- 0% vs 0% NCT00603512
- 6.6% vs 3.1% NCT00147498
- 45.9% vs 17.6% NCT00550446
- 39.2% vs 31.4% NCT00413660
- 42.6% vs 17.6% NCT00550446
- 40.5% vs 31.4% NCT00413660
- 42.6% vs 20.6% NCT00550446
- 36.5% vs 21.6% NCT00413660
- 69.8% vs 7.7% NCT00687193
- 45.9% vs 10.2% NCT00550446
- 50.8% vs 6.8% NCT00550446
- 62.3% vs 1.9% NCT00687193
- 29.5% vs 8.5% NCT00550446
- 36.1% vs 6.8% NCT00550446
- 54.7% vs 1.9% NCT00687193
- 31.1% vs 5.1% NCT00550446
- 32.1% vs 0% NCT00687193
- 18.0% vs 1.7% NCT00550446
- 25% vs 2.9% NCT00413660
- 15% vs 2.9% NCT00413660
- 57.7% vs 14.3% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 50% vs 7.1% NCT00603512
- 28.4% vs 17.4% NCT00413660
- 27.0% vs 8.7% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 20.3% vs 2.9% NCT00413660
- 26.9% vs 0% NCT00603512
- 4.0% vs 2.9% NCT00413660
- 45.1% vs 13.3% NCT00147498
- 50.7% vs 6.2% NCT00147498
- 42.0% vs 6.2% NCT00147498
- 29.0% vs 3.1% NCT00147498
- 18.8% vs 3.1% NCT00147498
- 46.3% vs 31.4% NCT00413660
- 47.8% vs 31.4% NCT00413660
- 41.8% vs 21.6% NCT00413660
- 36.3% vs 17.4% NCT00413660
- 32.5% vs 17.4% NCT00413660
- 27.5% vs 8.7% NCT00413660
- 7.7% vs 0% NCT00603512
- 54.4% vs 17.6% NCT00550446
- 46.7% vs 31.4% NCT00413660
- 59.6% vs 17.6% NCT00550446
- 48% vs 31.4% NCT00413660
- 56.1% vs 20.6% NCT00550446
- 40% vs 21.6% NCT00413660
- 72.2% vs 7.7% NCT00687193
- 50.9% vs 10.2% NCT00550446
- 44% vs 17.4% NCT00413660
- 43.9% vs 6.8% NCT00550446
- 66.7% vs 1.9% NCT00687193
- 49.1% vs 8.5% NCT00550446
- 41.3% vs 17.4% NCT00413660
- 30.4% vs 13.3% NCT00147498
- 42.1% vs 6.8% NCT00550446
- 32% vs 8.7% NCT00413660
- 53.6% vs 6.2% NCT00147498
- 46.3% vs 1.9% NCT00687193
- 40.4% vs 5.1% NCT00550446
- 26.7% vs 2.9% NCT00413660
- 42.0% vs 6.2% NCT00147498
- 22.2% vs 0% NCT00687193
- 17.5% vs 1.7% NCT00550446
- 17.3% vs 2.9% NCT00413660
- 23.2% vs 3.1% NCT00147498
- 8.7% vs 3.1% NCT00147498
- 44.1% vs 17.6% NCT00550446
- 34.5% vs 31.4% NCT00413660
- 44.1% vs 17.6% NCT00550446
- 45.5% vs 31.4% NCT00413660
- 38.2% vs 20.6% NCT00550446
- 43.6% vs 21.6% NCT00413660
- 26.4% vs 7.7% NCT00687193
- 25.5% vs 10.2% NCT00550446
- 44.4% vs 14.3% NCT00603512
- 29.4% vs 17.4% NCT00413660
- 17.6% vs 6.8% NCT00550446
- 37.7% vs 1.9% NCT00687193
- 21.6% vs 8.5% NCT00550446
- 29.6% vs 7.1% NCT00603512
- 32.4% vs 17.4% NCT00413660
- 15.7% vs 6.8% NCT00550446
- 29.4% vs 8.7% NCT00413660
- 22.6% vs 1.9% NCT00687193
- 13.7% vs 5.1% NCT00550446
- 22.2% vs 3.6% NCT00603512
- 16.2% vs 2.9% NCT00413660
- 9.4% vs 0% NCT00687193
- 7.8% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 5.9% vs 2.9% NCT00413660
- 3.7% vs 0% NCT00603512
- 10.8% vs 17.6% NCT00550446
- 44.9% vs 31.4% NCT00413660
- 18.9% vs 17.6% NCT00550446
- 38.8% vs 31.4% NCT00413660
- 18.9% vs 20.6% NCT00550446
- 38.8% vs 21.6% NCT00413660
- 13.5% vs 7.7% NCT00687193
- 11.1% vs 10.2% NCT00550446
- 32.1% vs 14.3% NCT00603512
- 22.9% vs 17.4% NCT00413660
- 13.0% vs 6.8% NCT00550446
- 11.5% vs 1.9% NCT00687193
- 13.0% vs 8.5% NCT00550446
- 28.6% vs 7.1% NCT00603512
- 17.1% vs 17.4% NCT00413660
- 14.8% vs 6.8% NCT00550446
- 10% vs 8.7% NCT00413660
- 9.6% vs 1.9% NCT00687193
- 9.3% vs 5.1% NCT00550446
- 10.7% vs 3.6% NCT00603512
- 4.3% vs 2.9% NCT00413660
- 1.9% vs 0% NCT00687193
- 1.9% vs 1.7% NCT00550446
- 7.1% vs 0% NCT00603512
- 1.4% vs 2.9% NCT00413660
- 67.4% vs 45.7% NCT01059864
- 48% vs 42.6% NCT01059864
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 31.4% NCT00413660
- 0% vs 21.6% NCT00413660
- 7.1% vs 0% NCT00603512
- 40% vs 0% NCT00976599
- 41.6% vs 36.7% NCT02092467
- 36.3% vs 31.7% NCT02092467
- 42.6% vs 39.8% NCT02092467
- 27.6% vs 23.2% NCT02092467
- 43.4% vs 39.8% NCT02092467
- 44.8% vs 40.1% NCT02092467
- 43.5% vs 42% NCT02092467
- 41.7% vs 41.9% NCT02092467
- 42.7% vs 40.8% NCT02092467
- 42.6% vs 41.1% NCT02092467
- 41.2% vs 42% NCT02092467
- 40.2% vs 40.9% NCT02092467
- 41.4% vs 40.8% NCT02092467
- 40.9% vs 38.7% NCT02092467
- 40.7% vs 40.5% NCT02092467
- 35.8% vs 35.8% NCT02092467
- 29% vs 29.2% NCT02092467
- 24.1% vs 23.8% NCT02092467
- 19.5% vs 18.5% NCT02092467
- 13.7% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 6.9% vs 7.1% NCT02092467
- 3.6% vs 3.8% NCT02092467
- 1.1% vs 1.9% NCT02092467
- 0.2% vs 0.5% NCT02092467
- 42.2% vs 36.7% NCT02092467
- 38.5% vs 31.7% NCT02092467
- 44.7% vs 39.8% NCT02092467
- 31% vs 23.2% NCT02092467
- 44.9% vs 39.8% NCT02092467
- 45.9% vs 40.1% NCT02092467
- 44.2% vs 42% NCT02092467
- 42.8% vs 41.9% NCT02092467
- 42.3% vs 40.8% NCT02092467
- 41.3% vs 41.1% NCT02092467
- 41.8% vs 42% NCT02092467
- 42% vs 40.9% NCT02092467
- 38.9% vs 40.8% NCT02092467
- 40.4% vs 38.7% NCT02092467
- 39.7% vs 40.5% NCT02092467
- 33% vs 35.8% NCT02092467
- 26.4% vs 29.2% NCT02092467
- 22% vs 23.8% NCT02092467
- 18.6% vs 18.5% NCT02092467
- 14.4% vs 14.4% NCT02092467
- 10.4% vs 10.3% NCT02092467
- 7.1% vs 7.1% NCT02092467
- 4.7% vs 3.8% NCT02092467
- 1.4% vs 1.9% NCT02092467
- 0.4% vs 0.5% NCT02092467
- upadacitinib
- 52.1% vs 28.3%vs MethotrexateNCT02706873
41 other results
- 56.4% vs 28.3% NCT02706873
- 38% vs 14.9% NCT02675426
- 34.1% vs 11.8% NCT02706847
- 40.8% vs 8.3% NCT02955212
- 43.4% vs 14.9% NCT02675426
- 35.8% vs 11.8% NCT02706847
- 65.3% vs 16.3% NCT02720523
- 58% vs 16.3% NCT02720523
- 40.8% vs 16.3% NCT02720523
- 60.3% vs 33.4% NCT02706873
- 41.9% vs 15.3% NCT02706951
- 65.6% vs 33.4% NCT02706873
- 52.1% vs 15.3% NCT02706951
- 66.7% vs 21.4% NCT02706873
- 71.4% vs 21.4% NCT02706873
- 60% vs 21.4% NCT02706873
- 29.3% vs 21.1% NCT03682705
- 19.5% vs 5.3% NCT03682705
- 17.1% vs 10.5% NCT03682705
- 4.9% vs 0% NCT03682705
- 43.8% vs 19.6% NCT02066389
- 12.8% vs 21.1% NCT03682705
- 12.8% vs 5.3% NCT03682705
- 2.6% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 44.7% vs 19.6% NCT02066389
- 40% vs 17% NCT01960855
- 45.2% vs 21.1% NCT03682705
- 41.9% vs 5.3% NCT03682705
- 19.4% vs 10.5% NCT03682705
- 16.1% vs 0% NCT03682705
- 50% vs 19.6% NCT02066389
- 43.6% vs 17% NCT01960855
- 49% vs 19.6% NCT02066389
- 38.5% vs 17% NCT01960855
- 17.1% vs 21.1% NCT03682705
- 7.3% vs 5.3% NCT03682705
- 4.9% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 39.6% vs 19.6% NCT02066389
- 24.1% vs 17% NCT01960855
ACR70
- tofacitinib
- 25.4% vs 12.1%vs MTXNCT01039688
271 other results
- 37.3% vs 12.1% NCT01039688
- 13.2% vs 3.2% NCT00856544
- 19.9% vs 1.9% NCT00853385
- 14.6% vs 1.3% NCT00847613
- 11.9% vs 3.2% NCT00856544
- 15.3% vs 5.8% NCT00814307
- 8.4% vs 1.9% NCT00856544
- 12.2% vs 1.9% NCT00853385
- 10.7% vs 2.6% NCT00847613
- 13.6% vs 1.5% NCT00960440
- 10.0% vs 3.3% NCT00814307
- 9% vs 1.3% NCT00856544
- 5.0% vs 1.7% NCT00814307
- 3.5% vs 0% NCT00856544
- 2.6% vs 0.9% NCT00853385
- 3.9% vs 0% NCT00847613
- 7.6% vs 0% NCT00960440
- 2.1% vs 0% NCT00814307
- 0.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 16.2% vs 3.2% NCT00856544
- 21.9% vs 1.9% NCT00853385
- 22.3% vs 1.3% NCT00847613
- 18.1% vs 3.2% NCT00856544
- 20.3% vs 5.8% NCT00814307
- 14.2% vs 1.9% NCT00856544
- 14.8% vs 1.9% NCT00853385
- 17.1% vs 2.6% NCT00847613
- 10.5% vs 1.5% NCT00960440
- 19.0% vs 3.3% NCT00814307
- 10.4% vs 1.3% NCT00856544
- 9.1% vs 1.7% NCT00814307
- 7.1% vs 0% NCT00856544
- 4.1% vs 0.9% NCT00853385
- 3.6% vs 0% NCT00847613
- 6.8% vs 0% NCT00960440
- 4.6% vs 0% NCT00814307
- 2.3% vs 0% NCT00856544
- 2.3% vs 0% NCT00960440
- 19.9% vs 5.5% NCT01039688
- 18.4% vs 11.1% NCT00853385
- 29.2% vs 13.2% NCT01039688
- 16.2% vs 3.3% NCT01039688
- 5.2% vs 0.6% NCT01039688
- 23.0% vs 16.6% NCT00853385
- 28.7% vs 15.4% NCT01039688
- 30.1% vs 17.0% NCT01039688
- 32.2% vs 15.9% NCT01039688
- 32.2% vs 17.6% NCT01039688
- 34.1% vs 15.4% NCT01039688
- 26.6% vs 5.5% NCT01039688
- 21.9% vs 11.1% NCT00853385
- 37.9% vs 13.2% NCT01039688
- 23.0% vs 3.3% NCT01039688
- 9.2% vs 0.6% NCT01039688
- 23.5% vs 16.6% NCT00853385
- 37.9% vs 15.4% NCT01039688
- 37.9% vs 17.0% NCT01039688
- 36.6% vs 15.9% NCT01039688
- 36.8% vs 17.6% NCT01039688
- 37.6% vs 15.4% NCT01039688
- 22.4% vs 11.8% NCT00550446
- 21.1% vs 9.8% NCT00413660
- 18.4% vs 8.8% NCT00550446
- 23.9% vs 13.7% NCT00413660
- 20.4% vs 0% NCT00550446
- 18.3% vs 9.8% NCT00413660
- 26.9% vs 1.9% NCT00687193
- 14.3% vs 3.4% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 18.3% vs 5.8% NCT00413660
- 16.3% vs 1.7% NCT00550446
- 25% vs 1.9% NCT00687193
- 8.2% vs 1.7% NCT00550446
- 33.3% vs 3.6% NCT00603512
- 11.3% vs 5.8% NCT00413660
- 8.9% vs 8.9% NCT00147498
- 4.1% vs 1.7% NCT00550446
- 16.9% vs 4.3% NCT00413660
- 13.1% vs 3.1% NCT00147498
- 17.3% vs 0% NCT00687193
- 2.0% vs 1.7% NCT00550446
- 14.8% vs 0% NCT00603512
- 0% vs 1.4% NCT00413660
- 9.8% vs 1.5% NCT00147498
- 1.9% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 11.1% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 4.9% vs 1.5% NCT00147498
- 0% vs 0% NCT00603512
- 1.6% vs 0% NCT00147498
- 37.7% vs 11.8% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 31.1% vs 8.8% NCT00550446
- 24.3% vs 13.7% NCT00413660
- 29.5% vs 0% NCT00550446
- 18.9% vs 9.8% NCT00413660
- 49.1% vs 1.9% NCT00687193
- 24.6% vs 3.4% NCT00550446
- 12.2% vs 5.8% NCT00413660
- 37.7% vs 1.9% NCT00687193
- 16.2% vs 5.8% NCT00413660
- 9.5% vs 4.3% NCT00413660
- 26.4% vs 0% NCT00687193
- 11.5% vs 1.7% NCT00550446
- 9.4% vs 0% NCT00687193
- 3.3% vs 0% NCT00550446
- 27.4% vs 8.9% NCT00147498
- 27.5% vs 3.1% NCT00147498
- 21.7% vs 1.5% NCT00147498
- 10.1% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 28.4% vs 9.8% NCT00413660
- 28.4% vs 13.7% NCT00413660
- 22.4% vs 9.8% NCT00413660
- 23.8% vs 5.8% NCT00413660
- 17.5% vs 5.8% NCT00413660
- 12.5% vs 4.3% NCT00413660
- 12.5% vs 1.4% NCT00413660
- 2.5% vs 0% NCT00413660
- 34.6% vs 3.6% NCT00603512
- 26.2% vs 1.7% NCT00550446
- 18.0% vs 1.7% NCT00550446
- 26.9% vs 3.6% NCT00603512
- 19.7% vs 1.7% NCT00550446
- 7.7% vs 0% NCT00603512
- 14.9% vs 1.4% NCT00413660
- 3.9% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 3.9% vs 0% NCT00603512
- 33.3% vs 11.8% NCT00550446
- 32% vs 9.8% NCT00413660
- 31.6% vs 8.8% NCT00550446
- 28% vs 13.7% NCT00413660
- 33.3% vs 0% NCT00550446
- 24% vs 9.8% NCT00413660
- 51.9% vs 1.9% NCT00687193
- 26.3% vs 3.4% NCT00550446
- 24% vs 5.8% NCT00413660
- 21.1% vs 1.7% NCT00550446
- 40.7% vs 1.9% NCT00687193
- 24.6% vs 1.7% NCT00550446
- 16% vs 5.8% NCT00413660
- 14.3% vs 8.9% NCT00147498
- 17.5% vs 1.7% NCT00550446
- 16% vs 4.3% NCT00413660
- 21.7% vs 3.1% NCT00147498
- 16.7% vs 0% NCT00687193
- 8.8% vs 1.7% NCT00550446
- 13.3% vs 1.4% NCT00413660
- 17.4% vs 1.5% NCT00147498
- 7.4% vs 0% NCT00687193
- 7.0% vs 0% NCT00550446
- 6.7% vs 0% NCT00413660
- 4.3% vs 1.5% NCT00147498
- 4.3% vs 0% NCT00147498
- 23.5% vs 11.8% NCT00550446
- 23.6% vs 9.8% NCT00413660
- 17.6% vs 8.8% NCT00550446
- 29.1% vs 13.7% NCT00413660
- 26.5% vs 0% NCT00550446
- 21.8% vs 9.8% NCT00413660
- 13.2% vs 1.9% NCT00687193
- 11.8% vs 3.4% NCT00550446
- 14.8% vs 3.6% NCT00603512
- 20.6% vs 5.8% NCT00413660
- 7.8% vs 1.7% NCT00550446
- 13.2% vs 1.9% NCT00687193
- 3.9% vs 1.7% NCT00550446
- 7.4% vs 3.6% NCT00603512
- 14.7% vs 5.8% NCT00413660
- 2.0% vs 1.7% NCT00550446
- 13.2% vs 4.3% NCT00413660
- 3.8% vs 0% NCT00687193
- 5.9% vs 1.7% NCT00550446
- 7.4% vs 0% NCT00603512
- 7.3% vs 1.4% NCT00413660
- 0% vs 0% NCT00687193
- 2.0% vs 0% NCT00550446
- 3.7% vs 0% NCT00603512
- 1.5% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 8.1% vs 11.8% NCT00550446
- 28.6% vs 9.8% NCT00413660
- 10.8% vs 8.8% NCT00550446
- 20.4% vs 13.7% NCT00413660
- 10.8% vs 0% NCT00550446
- 16.3% vs 9.8% NCT00413660
- 7.5% vs 1.9% NCT00687193
- 5.6% vs 3.4% NCT00550446
- 7.1% vs 3.6% NCT00603512
- 4.3% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 5.7% vs 1.9% NCT00687193
- 9.3% vs 1.7% NCT00550446
- 3.6% vs 3.6% NCT00603512
- 8.6% vs 5.8% NCT00413660
- 3.7% vs 1.7% NCT00550446
- 1.4% vs 4.3% NCT00413660
- 1.9% vs 0% NCT00687193
- 0% vs 1.7% NCT00550446
- 0% vs 0% NCT00687193
- 1.9% vs 0% NCT00550446
- 34.8% vs 30.4% NCT01059864
- 20% vs 19.1% NCT01059864
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 9.8% NCT00413660
- 0% vs 13.7% NCT00413660
- 0% vs 9.8% NCT00413660
- 3.6% vs 0% NCT00603512
- 2.9% vs 1.4% NCT00413660
- 0% vs 0% NCT00603512
- 1.4% vs 0% NCT00413660
- 0% vs 0% NCT00603512
- 6.7% vs 0% NCT00976599
- 19.4% vs 16.1% NCT02092467
- 17.4% vs 13.7% NCT02092467
- 22.5% vs 20.1% NCT02092467
- 10.4% vs 7.8% NCT02092467
- 23.2% vs 19.6% NCT02092467
- 24.7% vs 21% NCT02092467
- 24.6% vs 22.4% NCT02092467
- 24.9% vs 22.2% NCT02092467
- 24% vs 22.6% NCT02092467
- 25.7% vs 23.6% NCT02092467
- 25.4% vs 24.7% NCT02092467
- 24.5% vs 24.5% NCT02092467
- 24.9% vs 24.2% NCT02092467
- 25.5% vs 23.3% NCT02092467
- 25.8% vs 23.6% NCT02092467
- 21.5% vs 20.5% NCT02092467
- 17.6% vs 16.4% NCT02092467
- 14.8% vs 13.7% NCT02092467
- 10.9% vs 11% NCT02092467
- 8.8% vs 8.1% NCT02092467
- 5.4% vs 6.3% NCT02092467
- 4% vs 4.4% NCT02092467
- 1.7% vs 2.4% NCT02092467
- 0.5% vs 1% NCT02092467
- 0.1% vs 0.3% NCT02092467
- 22.7% vs 16.1% NCT02092467
- 18.4% vs 13.7% NCT02092467
- 25.2% vs 20.1% NCT02092467
- 13.3% vs 7.8% NCT02092467
- 25.6% vs 19.6% NCT02092467
- 26.8% vs 21% NCT02092467
- 26.2% vs 22.4% NCT02092467
- 25.4% vs 22.2% NCT02092467
- 26.5% vs 22.6% NCT02092467
- 26.8% vs 23.6% NCT02092467
- 27.3% vs 24.7% NCT02092467
- 26.9% vs 24.5% NCT02092467
- 23.6% vs 24.2% NCT02092467
- 24.8% vs 23.3% NCT02092467
- 23.5% vs 23.6% NCT02092467
- 20.5% vs 20.5% NCT02092467
- 15.7% vs 16.4% NCT02092467
- 13.4% vs 13.7% NCT02092467
- 11.2% vs 11% NCT02092467
- 8.7% vs 8.1% NCT02092467
- 5.7% vs 6.3% NCT02092467
- 3.9% vs 4.4% NCT02092467
- 2.6% vs 2.4% NCT02092467
- 1% vs 1% NCT02092467
- 0.3% vs 0.3% NCT02092467
- upadacitinib
- 20.8% vs 5.9%+14.9 vs placeboNCT02675426
41 other results
- 11.6% vs 6.5% NCT02706847
- 21.3% vs 3.6% NCT02955212
- 26.5% vs 5.9% NCT02675426
- 23% vs 6.5% NCT02706847
- 34.7% vs 2% NCT02720523
- 28% vs 2% NCT02720523
- 20.4% vs 2% NCT02720523
- 44.5% vs 18.5% NCT02706873
- 22.6% vs 2.8% NCT02706951
- 32.5% vs 14% NCT02706873
- 49.7% vs 18.5% NCT02706873
- 33% vs 2.8% NCT02706951
- 36.9% vs 14% NCT02706873
- 51.9% vs 0% NCT02706873
- 64.3% vs 0% NCT02706873
- 34.5% vs 0% NCT02706873
- 14.6% vs 15.8% NCT03682705
- 4.9% vs 0% NCT03682705
- 4.9% vs 0% NCT03682705
- 2.4% vs 0% NCT03682705
- 25% vs 6.5% NCT02066389
- 5.1% vs 15.8% NCT03682705
- 2.6% vs 0% NCT03682705
- 2.6% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 27.7% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 25.8% vs 15.8% NCT03682705
- 17.7% vs 0% NCT03682705
- 9.7% vs 0% NCT03682705
- 8.1% vs 0% NCT03682705
- 16% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 30.6% vs 6.5% NCT02066389
- 26.9% vs 3.6% NCT01960855
- 9.8% vs 15.8% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 23.4% vs 6.5% NCT02066389
- 13% vs 3.6% NCT01960855
DAS28-CRP remission
- tofacitinib
- 23.0% vs 5.2%+17.8 vs placeboNCT00847613
174 other results
- 20.4% vs 5.2% NCT00847613
- 11.3% vs 2.0% NCT00847613
- 36.4% vs 5.2% NCT00847613
- 26.9% vs 5.2% NCT00847613
- 9.1% vs 2.0% NCT00847613
- 31.3% vs 15.2% NCT01039688
- 25.9% vs 9.8% NCT01039688
- 36.2% vs 17.4% NCT01039688
- 20.4% vs 5.4% NCT01039688
- 7.4% vs 2.7% NCT01039688
- 36.5% vs 20.6% NCT01039688
- 37.6% vs 19.6% NCT01039688
- 38.4% vs 19.0% NCT01039688
- 37.1% vs 17.4% NCT01039688
- 38.4% vs 18.5% NCT01039688
- 47.2% vs 15.2% NCT01039688
- 37.8% vs 9.8% NCT01039688
- 45.7% vs 17.4% NCT01039688
- 28.7% vs 5.4% NCT01039688
- 14.1% vs 2.7% NCT01039688
- 49.5% vs 20.6% NCT01039688
- 49.2% vs 19.6% NCT01039688
- 44.7% vs 19.0% NCT01039688
- 44.7% vs 17.4% NCT01039688
- 43.9% vs 18.5% NCT01039688
- 65.9% vs 30% NCT00550446
- 22% vs 15% NCT00550446
- 41.5% vs 19.4% NCT00413660
- 68.9% vs 16.7% NCT00550446
- 20% vs 5.6% NCT00550446
- 35.1% vs 13.9% NCT00413660
- 69.6% vs 35% NCT00550446
- 28.3% vs 15% NCT00550446
- 24.1% vs 8.1% NCT00413660
- 62.2% vs 6.7% NCT00550446
- 24.4% vs 6.7% NCT00550446
- 16.7% vs 6.7% NCT00413660
- 65.8% vs 3.3% NCT00550446
- 21.7% vs 4.3% NCT00550446
- 66.7% vs 9.7% NCT00550446
- 14.9% vs 4.4% NCT00550446
- 19.4% vs 6.9% NCT00413660
- 56.4% vs 5.9% NCT00550446
- 8.9% vs 1.9% NCT00550446
- 13.6% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 4.4% vs 1.9% NCT00550446
- 8.1% vs 3.3% NCT00413660
- 62.5% vs 2.7% NCT00550446
- 4.2% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 72.7% vs 30% NCT00550446
- 36.4% vs 15% NCT00550446
- 36.5% vs 19.4% NCT00413660
- 88.7% vs 16.7% NCT00550446
- 43.4% vs 5.6% NCT00550446
- 37.1% vs 13.9% NCT00413660
- 78.2% vs 35% NCT00550446
- 36.4% vs 15% NCT00550446
- 30.2% vs 8.1% NCT00413660
- 75.6% vs 6.7% NCT00550446
- 33.3% vs 6.7% NCT00550446
- 32.3% vs 6.7% NCT00413660
- 90.7% vs 3.3% NCT00550446
- 31.6% vs 4.3% NCT00550446
- 78.6% vs 9.7% NCT00550446
- 21.4% vs 4.4% NCT00550446
- 21.3% vs 6.9% NCT00413660
- 79.5% vs 5.9% NCT00550446
- 24.1% vs 1.9% NCT00550446
- 24.2% vs 3.5% NCT00413660
- 83.7% vs 5.7% NCT00550446
- 17.5% vs 1.9% NCT00550446
- 19.1% vs 3.3% NCT00413660
- 71.1% vs 2.7% NCT00550446
- 5% vs 0% NCT00550446
- 4.4% vs 3.3% NCT00413660
- 32.7% vs 19.4% NCT00413660
- 30.9% vs 13.9% NCT00413660
- 29.1% vs 8.1% NCT00413660
- 24.6% vs 6.7% NCT00413660
- 20.9% vs 6.9% NCT00413660
- 10.1% vs 3.5% NCT00413660
- 10% vs 3.3% NCT00413660
- 4.0% vs 3.3% NCT00413660
- 84.6% vs 30% NCT00550446
- 50% vs 15% NCT00550446
- 39.3% vs 19.4% NCT00413660
- 76.9% vs 16.7% NCT00550446
- 42.3% vs 5.6% NCT00550446
- 38.6% vs 13.9% NCT00413660
- 82.4% vs 35% NCT00550446
- 43.1% vs 15% NCT00550446
- 37.9% vs 8.1% NCT00413660
- 68.6% vs 6.7% NCT00550446
- 40.4% vs 6.7% NCT00550446
- 37.1% vs 6.7% NCT00413660
- 79.4% vs 3.3% NCT00550446
- 38.5% vs 4.3% NCT00550446
- 75% vs 9.7% NCT00550446
- 41.5% vs 4.4% NCT00550446
- 23.9% vs 6.9% NCT00413660
- 67.6% vs 5.9% NCT00550446
- 32.7% vs 1.9% NCT00550446
- 22.7% vs 3.5% NCT00413660
- 62.2% vs 5.7% NCT00550446
- 15.1% vs 1.9% NCT00550446
- 16.9% vs 3.3% NCT00413660
- 66.7% vs 2.7% NCT00550446
- 7.0% vs 0% NCT00550446
- 13.2% vs 3.3% NCT00413660
- 46.4% vs 30% NCT00550446
- 39.3% vs 15% NCT00550446
- 35.7% vs 19.4% NCT00413660
- 58.6% vs 16.7% NCT00550446
- 20.7% vs 5.6% NCT00550446
- 43.2% vs 13.9% NCT00413660
- 53.3% vs 35% NCT00550446
- 30% vs 15% NCT00550446
- 41.9% vs 8.1% NCT00413660
- 42.9% vs 6.7% NCT00550446
- 8.9% vs 6.7% NCT00550446
- 30.9% vs 6.7% NCT00413660
- 53.3% vs 3.3% NCT00550446
- 8.5% vs 4.3% NCT00550446
- 46.7% vs 9.7% NCT00550446
- 12.8% vs 4.4% NCT00550446
- 22.0% vs 6.9% NCT00413660
- 43.3% vs 5.9% NCT00550446
- 12.8% vs 1.9% NCT00550446
- 19.7% vs 3.5% NCT00413660
- 33.3% vs 5.7% NCT00550446
- 6.5% vs 1.9% NCT00550446
- 14.8% vs 3.3% NCT00413660
- 33.3% vs 2.7% NCT00550446
- 4% vs 0% NCT00550446
- 3.2% vs 3.3% NCT00413660
- 33.3% vs 30% NCT00550446
- 16.7% vs 15% NCT00550446
- 23.1% vs 19.4% NCT00413660
- 46.2% vs 16.7% NCT00550446
- 19.2% vs 5.6% NCT00550446
- 20.5% vs 13.9% NCT00413660
- 48.1% vs 35% NCT00550446
- 22.2% vs 15% NCT00550446
- 14.3% vs 8.1% NCT00413660
- 22.2% vs 6.7% NCT00550446
- 9.3% vs 6.7% NCT00550446
- 6.6% vs 6.7% NCT00413660
- 26.3% vs 3.3% NCT00550446
- 10.9% vs 4.3% NCT00550446
- 25.6% vs 9.7% NCT00550446
- 2.1% vs 4.4% NCT00550446
- 7.9% vs 6.9% NCT00413660
- 20.5% vs 5.9% NCT00550446
- 8.5% vs 1.9% NCT00550446
- 3.2% vs 3.5% NCT00413660
- 30% vs 5.7% NCT00550446
- 6% vs 1.9% NCT00550446
- 4.6% vs 3.3% NCT00413660
- 25.6% vs 2.7% NCT00550446
- 1.9% vs 0% NCT00550446
- 1.6% vs 3.3% NCT00413660
- 16.7% vs 19.4% NCT00413660
- 0% vs 13.9% NCT00413660
- 11.1% vs 8.1% NCT00413660
- 15.4% vs 19.4% NCT00413660
- 15.4% vs 13.9% NCT00413660
- 23.1% vs 8.1% NCT00413660
- 25% vs 19.4% NCT00413660
- 28.6% vs 13.9% NCT00413660
- 9.5% vs 8.1% NCT00413660
- 24% vs 22.4% NCT04413617
- 40.8% vs 22.4% NCT04413617
- upadacitinib
- 48.3% vs 18.5%vs MethotrexateNCT02706873
22 other results
- 50% vs 18.5% NCT02706873
- 30.8% vs 10% NCT02675426
- 29.6% vs 5.3% NCT02955212
- 28.3% vs 10% NCT02675426
- 57.1% vs 6.1% NCT02720523
- 50% vs 6.1% NCT02720523
- 36.7% vs 6.1% NCT02720523
- 28.1% vs 8.3% NCT02706951
- 30% vs 13.3% NCT03086343
- 40.5% vs 8.3% NCT02706951
- 70.4% vs 17.9% NCT02706873
- 82.1% vs 17.9% NCT02706873
- 67.3% vs 17.9% NCT02706873
- 19.5% vs 10.5% NCT03682705
- 22.4% vs 14.9% NCT02066389
- 7.7% vs 10.5% NCT03682705
- 42.9% vs 14.9% NCT02066389
- 32.3% vs 10.5% NCT03682705
- 34% vs 14.9% NCT02066389
- 38.8% vs 14.9% NCT02066389
- 9.8% vs 10.5% NCT03682705
- 36.7% vs 14.9% NCT02066389
HAQ-DI, change
- tofacitinib
- -0.5 vs -0.2−0.3 vs placeboNCT00814307
233 other results
- -0.5 vs -0.2 NCT00856544
- -0.5 vs -0.2 NCT00853385
- -0.3 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.5 vs -0.2 NCT00814307
- -0.5 vs -0.2 NCT00856544
- -0.6 vs -0.2 NCT00853385
- -0.4 vs -0.1 NCT00847613
- -0.4 vs -0.2 NCT00960440
- -0.8 vs -0.6 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -0.8 vs -0.7 NCT01039688
- -0.7 vs -0.3 NCT01039688
- -0.5 vs -0.2 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.9 vs -0.6 NCT01039688
- -0.8 vs -0.5 NCT01039688
- -0.9 vs -0.7 NCT01039688
- -0.8 vs -0.3 NCT01039688
- -0.6 vs -0.2 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -1 vs -0.7 NCT01039688
- -1.0 vs -0.7 NCT01039688
- -0.5 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.4 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.6 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.5 vs -0.2 NCT00550446
- -0.5 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00147498
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.4 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.3 vs 0.1 NCT00687193
- -0.2 vs -0.0 NCT00550446
- -0.3 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00147498
- -0.1 vs 0 NCT00603512
- -0.3 vs -0.1 NCT00147498
- -0.6 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00550446
- -0.4 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.6 vs -0.2 NCT00550446
- -0.6 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.5 vs -0.2 NCT00550446
- -0.5 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00687193
- -0.4 vs -0.1 NCT00550446
- -0.4 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.2 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.5 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.4 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00147498
- -0.7 vs -0.1 NCT00147498
- -0.6 vs -0.1 NCT00147498
- -0.4 vs -0.1 NCT00147498
- -0.7 vs -0.4 NCT00413660
- -0.7 vs -0.4 NCT00413660
- -0.6 vs -0.3 NCT00413660
- -0.6 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00413660
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0 NCT00603512
- -0.8 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.9 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.7 vs 0.2 NCT00687193
- -0.8 vs -0.2 NCT00550446
- -0.5 vs -0.1 NCT00413660
- -0.8 vs -0.2 NCT00550446
- -0.6 vs 0.2 NCT00687193
- -0.7 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.6 vs -0.2 NCT00147498
- -0.7 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.7 vs -0.2 NCT00147498
- -0.5 vs 0.0 NCT00687193
- -0.6 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.6 vs -0.1 NCT00147498
- -0.4 vs 0.1 NCT00687193
- -0.4 vs -0.0 NCT00550446
- -0.2 vs -0.1 NCT00413660
- -0.5 vs -0.1 NCT00147498
- -0.3 vs -0.1 NCT00147498
- -0.5 vs -0.4 NCT00550446
- -0.5 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.3 NCT00413660
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.5 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.2 NCT00687193
- -0.4 vs -0.2 NCT00550446
- -0.3 vs 0.0 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00413660
- -0.3 vs 0.0 NCT00687193
- -0.3 vs -0.1 NCT00550446
- -0.3 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.3 vs -0.0 NCT00550446
- -0.2 vs -0.0 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.6 vs -0.4 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.6 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00550446
- -0.5 vs -0.3 NCT00413660
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs -0.1 NCT00603512
- -0.4 vs -0.1 NCT00413660
- -0.4 vs -0.2 NCT00550446
- -0.2 vs 0.2 NCT00687193
- -0.3 vs -0.2 NCT00550446
- -0.4 vs 0.0 NCT00603512
- -0.3 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT00550446
- -0.3 vs -0.1 NCT00413660
- -0.1 vs 0.0 NCT00687193
- -0.1 vs -0.1 NCT00550446
- -0.2 vs -0.1 NCT00603512
- -0.2 vs -0.1 NCT00413660
- -0.1 vs 0.1 NCT00687193
- -0.1 vs -0.0 NCT00550446
- -0.1 vs -0.0 NCT00603512
- -0.1 vs -0.1 NCT00413660
- -0.3 vs -0.2 NCT01484561
- 0.1 vs -0.1 NCT01484561
- -0.4 vs -0.0 NCT01484561
- -0.5 vs -0.4 NCT00413660
- -0.4 vs -0.4 NCT00413660
- -0.5 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.1 vs -0.4 NCT00413660
- -0.1 vs -0.3 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.4 NCT00413660
- -0.2 vs -0.3 NCT00413660
- -0.1 vs 0 NCT00603512
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.4 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.4 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.6 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- -0.5 vs -0.5 NCT02092467
- upadacitinib
- -0.6 vs -0.3−0.3 vs placeboNCT02675426
32 other results
- -0.4 vs -0.2 NCT02706847
- -0.6 vs -0.2 NCT02955212
- -0.5 vs -0.3 NCT02675426
- -0.4 vs -0.2 NCT02706847
- -0.5 vs -0.1 NCT02720523
- -0.5 vs -0.1 NCT02720523
- -0.4 vs -0.1 NCT02720523
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.8 vs -0.5 NCT02706873
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.9 vs -0.5 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.8 vs -0.2 NCT02706873
- -0.3 vs -0.3 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.5 vs -0.3 NCT03682705
- -0.5 vs -0.2 NCT03682705
- -0.4 vs -0.4 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.2 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.2 vs -0.4 NCT03682705
- -0.2 vs -0.2 NCT03682705
Modified Sharp score, change
- tofacitinib
- 0.1 vs 0.5−0.3 vs placeboNCT00847613
7 other results
- 0.1 vs 0.5 NCT00847613
- 0.2 vs 0.7 NCT01039688
- 0.1 vs 0.7 NCT01039688
- 0.4 vs 1.2 NCT01039688
- 0.6 vs 2.1 NCT01039688
- 0.2 vs 1.2 NCT01039688
- 0.3 vs 2.1 NCT01039688
- upadacitinib
- 0.1 vs 0.7vs MethotrexateNCT02706873
4 other results
- 0.1 vs 0.7 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.9 vs 2.6 NCT02706873
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
17 other shared endpoints and safety
Coverage. tofacitinib: 21 of 21 rows · upadacitinib: 21 of 21 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tofacitinib Rows use multiple source trials | upadacitinib Rows use multiple source trials |
|---|---|---|
| Boolean Remission responder rate · % of participants | 8.33% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d NCT02092467 · Phase 4 show 1 more dose22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID NCT02092467 · Phase 4 | 9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mga,b,c,d NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CDAI absolute change · score | -31.23 vs -31.65 TNFi score @ 273wk5 mg BIDa,b,c,e NCT02092467 · Phase 4 show 1 more dose-31.08 vs -31.65 TNFi score @ 273wk10 mg BID NCT02092467 · Phase 4 | -17.5 vs -14.57 placebo score @ 12wk60 mga,b,c,e NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-16.7 vs -14.57 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -27 vs -14.57 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.51 vs -14.57 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CDAI Clinical Remission responder rate · % of participants | 16.67% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d NCT02092467 · Phase 4 show 1 more dose22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID NCT02092467 · Phase 4 | 7.3% (n=41) vs 5.3% (n=19) placebo @ 12wk60 mga,b,c,d NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses5.1% (n=39) vs 5.3% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 14.5% (n=62) vs 5.3% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 0% (n=41) vs 5.3% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CDAI Low Disease Activity responder rate · % of participants | 50% (n=1455) vs 53.33% (n=1451) TNFi @ 312wk5 mg BIDa,f,c,g,d NCT02092467 · Phase 4 show 1 more dose66.67% (n=1456) vs 53.33% (n=1451) TNFi @ 312wk10 mg BID NCT02092467 · Phase 4 | 40.3% (n=221) vs 19% (n=221) placebo @ 12wk15 mga,f,c,g,d NCT02675426 · Phase 3 show 1 more dose42% (n=219) vs 19% (n=221) placebo @ 12wk30 mg NCT02675426 · Phase 3 |
| CRP Change absolute change · mg | -23.97 vs 8.22 placebo mg @ 12wk5 mga,c NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-25.11 vs 8.22 placebo mg @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -26.14 vs 8.22 placebo mg @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -18.34 vs 8.22 placebo mg @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -8.88 vs 8.22 placebo mg @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence | -4.58 vs 1.45 placebo mg @ 12wk60 mga,c NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-5.78 vs 1.45 placebo mg @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -10.95 vs 1.45 placebo mg @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -0.81 vs 1.45 placebo mg @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| DAS Low Disease Activity responder rate · % of participants | 52.32% (n=367) vs 29.35% (n=184) MTX @ 104wk5 mg BIDa,c,g,h NCT01039688 · Phase 3 show 3 more doses34.8% (n=342) vs 15.79% (n=171) MTX @ 104wk5 mg BID NCT01039688 · Phase 3 56.85% (n=394) vs 29.35% (n=184) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 36.02% (n=372) vs 15.79% (n=171) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 | 59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mga,c,g,h NCT02706873 · Phase 3 show 1 more dose65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg NCT02706873 · Phase 3 |
| DAS28-CRP absolute change · score | -2.66 vs -2.53 PF-06651600 score @ 24wk11mg MRa,i,c NCT04413617 · Phase 2 · registry result, not featured evidence show 1 more dose-3.05 vs -2.53 PF-06651600 score @ 24wk400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination | -3.07 vs -2.15 Methotrexate score @ 24wk15 mga,i,c NCT02706873 · Phase 3 show 1 more dose-3.34 vs -2.15 Methotrexate score @ 24wk30 mg NCT02706873 · Phase 3 |
| DAS28-CRP LDAS responder rate · % of participants | 50% (n=1455) vs 73.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d NCT02092467 · Phase 4 show 1 more dose61.11% (n=1456) vs 73.33% (n=1451) TNFi @ 312wk10 mg BID NCT02092467 · Phase 4 | 22% (n=41) vs 21.1% (n=19) placebo @ 12wk60 mga,b,c,d NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses10.3% (n=39) vs 21.1% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 41.9% (n=62) vs 21.1% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 14.6% (n=41) vs 21.1% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| DAS28-ESR absolute change · score | -2.2 vs -0.1 placebo score @ 12wk5 mga,c NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-3.05 vs -0.1 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -2.98 vs -0.1 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -1.74 vs -0.1 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -1.1 vs -0.1 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence | -1.41 vs -1.18 placebo score @ 12wk60 mga,c NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-1.24 vs -1.18 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -2.53 vs -1.18 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -1.44 vs -1.18 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| FACIT-Fatigue absolute change · score | 7.47 vs 3.33 placebo score @ 12wk5 mga,i,c,g NCT00550446 · Phase 2 · registry result, not featured evidence show 4 more doses9.4 vs 3.33 placebo score @ 12wk10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 8.85 vs 3.33 placebo score @ 12wk15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 6 vs 3.33 placebo score @ 12wk3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.14 vs 3.33 placebo score @ 12wk1 mg NCT00550446 · Phase 2 · registry result, not featured evidence | 7.91 vs 2.96 placebo score @ 12wk15 mga,i,c,g NCT02675426 · Phase 3 show 1 more dose7.74 vs 2.96 placebo score @ 12wk30 mg NCT02675426 · Phase 3 |
| HAQ-DI responder rate · % of participants | 60.11% (n=366) vs 46.74% (n=184) MTX @ 104wk5 mg BIDa,j,c,k NCT01039688 · Phase 3 show 5 more doses56.83% (n=366) vs 43.48% (n=184) MTX @ 104wk5 mg BID NCT01039688 · Phase 3 53.28% (n=366) vs 37.5% (n=184) MTX @ 104wk5 mg BID NCT01039688 · Phase 3 65.05% (n=392) vs 46.74% (n=184) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 62.76% (n=392) vs 43.48% (n=184) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 59.44% (n=392) vs 37.5% (n=184) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 | 53.7% (n=41) vs 47.4% (n=19) placebo @ 12wk60 mga,j,c,k NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses43.6% (n=39) vs 47.4% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 58.1% (n=62) vs 47.4% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 43.9% (n=41) vs 47.4% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| mTSS no Progression responder rate · % of participants | 79.89% (n=348) vs 64.91% (n=171) MTX @ 104wk5 mg BIDa,c,g,h NCT01039688 · Phase 3 show 1 more dose83.65% (n=373) vs 64.91% (n=171) MTX @ 104wk10 mg BID NCT01039688 · Phase 3 | 87.5% (n=279) vs 77.7% (n=264) Methotrexate @ 24wk15 mga,c,g,h NCT02706873 · Phase 3 show 4 more doses80.8% (n=26) vs 46.2% (n=26) Methotrexate @ 24wk15 mg NCT02706873 · Phase 3 89.3% (n=270) vs 77.7% (n=264) Methotrexate @ 24wk30 mg NCT02706873 · Phase 3 79.2% (n=24) vs 46.2% (n=26) Methotrexate @ 24wk30 mg NCT02706873 · Phase 3 82.4% (n=51) vs 46.2% (n=26) Methotrexate @ 24wk7.5 mg NCT02706873 · Phase 3 |
| Patient Assessment of Arthritis Pain absolute change · score | -34.37 vs -1.06 placebo score @ 12wk5 mga,c NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-42.91 vs -1.06 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -43.79 vs -1.06 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -22.33 vs -1.06 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -18.38 vs -1.06 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence | -19.52 vs -23.37 placebo score @ 12wk60 mga,c NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-10.46 vs -23.37 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -32.27 vs -23.37 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -17.84 vs -23.37 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score | -34.59 vs -1.02 placebo score @ 12wk5 mga,c NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses-43.55 vs -1.02 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence -41.86 vs -1.02 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence -20.91 vs -1.02 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence -16.29 vs -1.02 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence | -19.47 vs -19.55 placebo score @ 12wk60 mga,c NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-8.45 vs -19.55 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -30.52 vs -19.55 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.4 vs -19.55 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Physician Global Assessment absolute change · score | -40.86 vs -38.62 PF-06651600 score @ 12wk11mg MRa,c NCT04413617 · Phase 2 · registry result, not featured evidence show 1 more dose-43.5 vs -38.62 PF-06651600 score @ 12wk400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination | -30.15 vs -23.19 placebo score @ 12wk60 mga,c NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-31.68 vs -23.19 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -46.98 vs -23.19 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -24.55 vs -23.19 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| SDAI absolute change · score | -32.27 vs -32.27 TNFi score @ 273wk5 mg BIDa,b,c,e NCT02092467 · Phase 4 show 1 more dose-32.12 vs -32.27 TNFi score @ 273wk10 mg BID NCT02092467 · Phase 4 | -18.01 vs -14.44 placebo score @ 12wk60 mga,b,c,e NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-17.12 vs -14.44 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.73 vs -14.44 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score | 6.22 vs -1.04 placebo score @ 12wk5 mga,i,c,g NCT00687193 · Phase 2 · registry result, not featured evidence show 4 more doses10.25 vs -1.04 placebo score @ 12wk10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 10.27 vs -1.04 placebo score @ 12wk15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 6.03 vs -1.04 placebo score @ 12wk3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.27 vs -1.04 placebo score @ 12wk1 mg NCT00687193 · Phase 2 · registry result, not featured evidence | 7.58 vs 3.03 placebo score @ 12wk15 mga,i,c,g NCT02675426 · Phase 3 show 1 more dose8.01 vs 3.03 placebo score @ 12wk30 mg NCT02675426 · Phase 3 |
| Dropout rate | 0%l NCT01262118 · Phase 1 show 80 more results4.9%5 mg NCT00814307 · Phase 3 11%10 mg NCT00814307 · Phase 3 17.9%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 20.8%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 26.5%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 21.4%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 n/a: no completion milestone5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 n/a: no completion milestone10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 19.5%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 23.1%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 28%10 mg BID NCT01039688 · Phase 3 27.7%5 mg BID NCT02092467 · Phase 4 31.5%10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.2%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 56.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 50.8%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 3.8% NCT02281552 · Phase 3 · registry result, not featured evidence 36.6%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 37.1%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 6.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 7.8%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 9.1%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 6.3% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.7%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 7.5%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 8%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 4.9%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.3%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 9.6%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 18.5%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 17.9%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 25%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 17.9%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 9.9%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.7%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 12.5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 12%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 10.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 9.9%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 4.9%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 24.6%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 13%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 9.3% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination | —15 mgl NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.6%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 8.2%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 12.6%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 14%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 7.3%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 7.4%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 4.7%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 4.8%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 9.7%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 4.1%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 12%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 7.3%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 12.8%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 6.5%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 14.6%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 10%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 14%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 6%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 12%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 9.1%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 16.4%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —l NCT01262118 · Phase 1 show 80 more results1.2%5 mg NCT00814307 · Phase 3 3.7%10 mg NCT00814307 · Phase 3 6.3%5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 —5 mg NCT00856544 · Phase 3 9.1%10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 11.8%5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 11.9%10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 11.2%5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 —5 mg NCT00847613 · Phase 3 8.2%10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 9%5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 —5 mg NCT00960440 · Phase 3 9%10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 —5 mg BID NCT01039688 · Phase 3 9.8%10 mg BID NCT01039688 · Phase 3 —5 mg BID NCT02092467 · Phase 4 —10 mg BID NCT02092467 · Phase 4 —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination —5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 23.1%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 2.9% NCT02281552 · Phase 3 · registry result, not featured evidence 25.9%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 22.9%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 1%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 1%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination — NCT00976599 · Phase 2 · registry result, not featured evidence — NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.5%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.8%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 14.3%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 14.3%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.1%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 1.4%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5.3%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 5%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence —20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.4%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence —3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence —1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 10.1%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 8.7%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 1% NCT01484561 · Phase 1 · registry result, not featured evidence —CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence —Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination | —15 mgl NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 1.4%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 4.1%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 5.7%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 3.5%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 5.5%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 2.3%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 1.4%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 0.6%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 2.4%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 1.6%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 2%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 10%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 3.6%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 10.9%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%l NCT01262118 · Phase 1 show 80 more results—5 mg NCT00814307 · Phase 3 —10 mg NCT00814307 · Phase 3 —5 mg NCT00856544 · Phase 3 1.6%5 mg NCT00856544 · Phase 3 2.2%5 mg NCT00856544 · Phase 3 2.9%5 mg NCT00856544 · Phase 3 —10 mg NCT00856544 · Phase 3 2.2%10 mg NCT00856544 · Phase 3 2.8%10 mg NCT00856544 · Phase 3 2.5%10 mg NCT00856544 · Phase 3 —5 mg twice daily NCT00853385 · Phase 3 4.3%5 mg twice daily NCT00853385 · Phase 3 4.2%5 mg twice daily NCT00853385 · Phase 3 5.9%5 mg twice daily NCT00853385 · Phase 3 —10 mg twice daily NCT00853385 · Phase 3 3.2%10 mg twice daily NCT00853385 · Phase 3 4%10 mg twice daily NCT00853385 · Phase 3 5%10 mg twice daily NCT00853385 · Phase 3 —5 mg NCT00847613 · Phase 3 5%5 mg NCT00847613 · Phase 3 3.5%5 mg NCT00847613 · Phase 3 3.7%5 mg NCT00847613 · Phase 3 —10 mg NCT00847613 · Phase 3 2.3%10 mg NCT00847613 · Phase 3 3.3%10 mg NCT00847613 · Phase 3 3.2%10 mg NCT00847613 · Phase 3 —5 mg NCT00960440 · Phase 3 4%5 mg NCT00960440 · Phase 3 1.5%5 mg NCT00960440 · Phase 3 —10 mg NCT00960440 · Phase 3 4%10 mg NCT00960440 · Phase 3 1.5%10 mg NCT00960440 · Phase 3 10.7%5 mg BID NCT01039688 · Phase 3 10.8%10 mg BID NCT01039688 · Phase 3 25.6%5 mg BID NCT02092467 · Phase 4 28.8%10 mg BID NCT02092467 · Phase 4 3.8%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 1.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 2.9%11 mg NCT02831855 · Phase 4 · registry result, not featured evidence · combination 10.4%5 mg NCT00413699 · Phase 3 · registry result, not featured evidence 30.8%5 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 29.7%10 mg BID NCT00413699 · Phase 3 · registry result, not featured evidence 4.8% NCT02281552 · Phase 3 · registry result, not featured evidence 29.1%5 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 26.7%10 mg BID NCT00661661 · Phase 3 · registry result, not featured evidence 2.9%11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence 0%400mg MR + 11mg MR NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5.5%5 mg Twice a Day NCT02147587 · Phase 2 · registry result, not featured evidence 3.6% NCT01359150 · Phase 2 · registry result, not featured evidence · combination 0% NCT00976599 · Phase 2 · registry result, not featured evidence 0% NCT01059864 · Phase 2 · registry result, not featured evidence · combination 3.8%5 mg NCT00687193 · Phase 2 · registry result, not featured evidence 3.8%10 mg NCT00687193 · Phase 2 · registry result, not featured evidence 1.9%15 mg NCT00687193 · Phase 2 · registry result, not featured evidence 5.7%3 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00687193 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00550446 · Phase 2 · registry result, not featured evidence 1.6%10 mg NCT00550446 · Phase 2 · registry result, not featured evidence 7%15 mg NCT00550446 · Phase 2 · registry result, not featured evidence 2.9%3 mg NCT00550446 · Phase 2 · registry result, not featured evidence 5.4%1 mg NCT00550446 · Phase 2 · registry result, not featured evidence 3.7%5 mg NCT00603512 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.7%3 mg NCT00603512 · Phase 2 · registry result, not featured evidence 3.6%1 mg NCT00603512 · Phase 2 · registry result, not featured evidence 5.6%5 mg NCT00413660 · Phase 2 · registry result, not featured evidence 1.4%10 mg NCT00413660 · Phase 2 · registry result, not featured evidence 6%20 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%20 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 8%15 mg NCT00413660 · Phase 2 · registry result, not featured evidence 7.3%3 mg NCT00413660 · Phase 2 · registry result, not featured evidence 0%3 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 2%1 mg NCT00413660 · Phase 2 · registry result, not featured evidence 4.8%1 mg to 5 mg (R) NCT00413660 · Phase 2 · registry result, not featured evidence 1.6%5 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 4.3%30 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 7.2%15 mg BID NCT00147498 · Phase 2 · registry result, not featured evidence 2.1% NCT01484561 · Phase 1 · registry result, not featured evidence 0%CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence 0%Methotrexate + CP-690,500 NCT01745055 · Phase 1 · registry result, not featured evidence · combination | 28.1%15 mgl NCT02675426 · Phase 3 show 55 more results4.5%15 mg NCT02675426 · Phase 3 10.6%15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.2%30 mg NCT02675426 · Phase 3 31.8%30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 15.5%15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 5%15 mg NCT02706873 · Phase 3 · monotherapy 21.5%15 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 6.4%30 mg NCT02706873 · Phase 3 · monotherapy 22.6%30 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 9.1%7.5 mg NCT02706873 · Phase 3 · monotherapy 23.6%7.5 mg NCT02706873 · Phase 3 · monotherapy 4%15 mg QD NCT03086343 · Phase 3 23.6%15 mg QD NCT03086343 · Phase 3 19%30 mg QD NCT03086343 · Phase 3 35.3%30 mg QD NCT03086343 · Phase 3 5.1%15 mg NCT02706951 · Phase 3 10.7%15 mg NCT02706951 · Phase 3 29.9%15 mg NCT02706951 · Phase 3 2.8%30 mg NCT02706951 · Phase 3 24.1%30 mg NCT02706951 · Phase 3 —15 mg NCT02706847 · Phase 3 15.2%15 mg NCT02706847 · Phase 3 5.5%15 mg NCT02706847 · Phase 3 36.9%15 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 29.6%30 mg NCT02706847 · Phase 3 17.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 7.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 21.9%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 27.3%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 13.8%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 22.5%12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 13.8%6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 0%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 5.1%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 4.1%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 6%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 4%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 1.8%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | l upper respiratory tract infection 19.4% headache 11.1% urinary tract infection 8.3% NCT01262118 · Phase 1 show 70 more results5 mg upper respiratory tract infection 4.1% (placebo 0%) gastroenteritis 2.2% (placebo 0%) nasopharyngitis 1.9% (placebo 0%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 3.5% (placebo 0%) diarrhoea 1.9% (placebo 0%) sinusitis 1.6% (placebo 2.5%) NCT00856544 · Phase 3 5 mg upper respiratory tract infection 6% (placebo 0%) nasopharyngitis 5.1% (placebo 0%) diarrhoea 4.4% (placebo 0%) NCT00856544 · Phase 3 10 mg nasopharyngitis 2.8% (placebo 0%) upper respiratory tract infection 2.8% (placebo 0%) oedema peripheral 2.5% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 5.7% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 0%) urinary tract infection 2.2% (placebo 1.2%) NCT00856544 · Phase 3 10 mg upper respiratory tract infection 7.2% (placebo 0%) diarrhoea 3.1% (placebo 0%) headache 3.1% (placebo 2.5%) NCT00856544 · Phase 3 5 mg twice daily nasopharyngitis 2.2% (placebo 1.7%) urinary tract infection 2.2% (placebo 0%) fall 1.7% (placebo 3.4%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) nasopharyngitis 3.1% (placebo 1.7%) bronchitis 2.7% (placebo 0%) NCT00853385 · Phase 3 5 mg twice daily upper respiratory tract infection 4.4% (placebo 0%) headache 3.9% (placebo 0%) nasopharyngitis 3.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily back pain 0.9% (placebo 0%) fall 0.9% (placebo 3.4%) nasopharyngitis 0.9% (placebo 1.7%) NCT00853385 · Phase 3 10 mg twice daily bronchitis 4% (placebo 0%) abdominal pain upper 2.8% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT00853385 · Phase 3 10 mg twice daily upper respiratory tract infection 3.5% (placebo 0%) headache 3% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00853385 · Phase 3 5 mg upper respiratory tract infection 4.7% (placebo 0%) nasopharyngitis 3.6% (placebo 4.9%) bronchitis 0.8% (placebo 0%) NCT00847613 · Phase 3 5 mg nasopharyngitis 5.5% (placebo 4.9%) upper respiratory tract infection 3.2% (placebo 0%) herpes zoster 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg headache 5.6% (placebo 0%) nasopharyngitis 4.4% (placebo 4.9%) hypertension 3.4% (placebo 0%) NCT00847613 · Phase 3 10 mg bronchitis 2.5% (placebo 0%) nasopharyngitis 2.5% (placebo 4.9%) upper respiratory tract infection 2.5% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 5.6% (placebo 4.9%) urinary tract infection 4.3% (placebo 0%) upper respiratory tract infection 3.8% (placebo 0%) NCT00847613 · Phase 3 10 mg nasopharyngitis 4.1% (placebo 4.9%) cough 2.8% (placebo 0%) diarrhoea 2.5% (placebo 0%) NCT00847613 · Phase 3 5 mg rheumatoid arthritis 3.5% (placebo 3%) bronchitis 3% (placebo 0%) nasopharyngitis 3% (placebo 3%) NCT00960440 · Phase 3 5 mg diarrhoea 6% (placebo 3.8%) nasopharyngitis 3.8% (placebo 3%) upper respiratory tract infection 3.8% (placebo 3%) NCT00960440 · Phase 3 10 mg upper respiratory tract infection 4% (placebo 3%) nasopharyngitis 2.5% (placebo 3%) back pain 2% (placebo 1.5%) NCT00960440 · Phase 3 10 mg headache 6% (placebo 0.8%) nasopharyngitis 4.5% (placebo 3%) diarrhoea 3.7% (placebo 3.8%) NCT00960440 · Phase 3 10 mg BID nasopharyngitis 9.8% blood creatine phosphokinase increased 9.1% upper respiratory tract infection 9.1% NCT01039688 · Phase 3 5 mg BID upper respiratory tract infection 21.9% bronchitis 15.2% urinary tract infection 13.1% NCT02092467 · Phase 4 10 mg BID upper respiratory tract infection 21.8% bronchitis 16.7% urinary tract infection 15.1% NCT02092467 · Phase 4 11 mg arthralgia 2.7% alanine aminotransferase increased 1.9% aspartate aminotransferase increased 1.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg alanine aminotransferase increased 3.8% bronchitis 2.6% nasopharyngitis 2.6% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 11 mg nasopharyngitis 5% upper respiratory tract infection 4.8% nausea 2.9% NCT02831855 · Phase 4 · registry result, not featured evidence · combination 5 mg bronchitis 1 6.3% alanine aminotransferase increased 0% anemia 0% NCT00413699 · Phase 3 · registry result, not featured evidence 5 mg BID upper respiratory tract infection 20.3% urinary tract infection 14.3% bronchitis 12.6% NCT00413699 · Phase 3 · registry result, not featured evidence 10 mg BID upper respiratory tract infection 18.3% nasopharyngitis 15.4% urinary tract infection 13.3% NCT00413699 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.6% NCT02281552 · Phase 3 · registry result, not featured evidence 5 mg BID nasopharyngitis 58% herpes zoster 15.5% fall 13.4% NCT00661661 · Phase 3 · registry result, not featured evidence 10 mg BID nasopharyngitis 68.6% herpes zoster 21% fall 19% NCT00661661 · Phase 3 · registry result, not featured evidence 11mg MR sars-cov-2 test positive 6.9% urinary tract infection 4.9% headache 3.9% NCT04413617 · Phase 2 · registry result, not featured evidence 400mg MR + 11mg MR urinary tract infection 6.8% sars-cov-2 test positive 3.9% headache 2.9% NCT04413617 · Phase 2 · registry result, not featured evidence · combination 5 mg Twice a Day arthralgia 5.5% (placebo 0%) rheumatoid arthritis 5.5% (placebo 15.8%) NCT02147587 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 5.4% (placebo 7.2%) headache 4.5% (placebo 0.9%) dizziness 2.7% (placebo 0%) NCT01359150 · Phase 2 · registry result, not featured evidence · combination fatigue 13.3% (placebo 0%) hypoaesthesia 13.3% (placebo 0%) nausea 13.3% (placebo 7.1%) NCT00976599 · Phase 2 · registry result, not featured evidence dyspepsia 4% (placebo 2.1%) oedema peripheral 4% (placebo 4.3%) oropharyngeal pain 4% (placebo 0%) NCT01059864 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 11.5% (placebo 11.5%) hypertension 5.8% (placebo 0%) dental caries 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 10 mg hyperlipidaemia 11.3% (placebo 0%) hypercholesterolaemia 5.7% (placebo 0%) nasopharyngitis 5.7% (placebo 11.5%) NCT00687193 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 14.8% (placebo 11.5%) low density lipoprotein increased 11.1% (placebo 0%) constipation 5.6% (placebo 3.8%) NCT00687193 · Phase 2 · registry result, not featured evidence 3 mg nasopharyngitis 7.5% (placebo 11.5%) headache 5.7% (placebo 1.9%) hypercholesterolaemia 3.8% (placebo 0%) NCT00687193 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 11.3% (placebo 11.5%) fall 5.7% (placebo 0%) abdominal discomfort 3.8% (placebo 1.9%) NCT00687193 · Phase 2 · registry result, not featured evidence 5 mg urinary tract infection 10.2% (placebo 5.9%) diarrhoea 6.1% (placebo 0%) bronchitis 4.1% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 10 mg headache 9.8% (placebo 2.9%) diarrhoea 6.6% (placebo 0%) hypertension 4.9% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 15 mg urinary tract infection 10.5% (placebo 5.9%) bronchitis 7% (placebo 0%) back pain 5.3% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 3 mg diarrhoea 8.8% (placebo 0%) back pain 5.9% (placebo 0%) bronchitis 5.9% (placebo 0%) NCT00550446 · Phase 2 · registry result, not featured evidence 1 mg urinary tract infection 8.1% (placebo 5.9%) diarrhoea 5.4% (placebo 0%) dizziness 5.4% (placebo 2.9%) NCT00550446 · Phase 2 · registry result, not featured evidence 5 mg alanine aminotransferase increased 22.2% (placebo 3.6%) aspartate aminotransferase increased 14.8% (placebo 3.6%) stomach discomfort 11.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 15.4% (placebo 14.3%) alanine aminotransferase increased 7.7% (placebo 3.6%) blood triglycerides increased 7.7% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 3 mg blood cholesterol increased 11.1% (placebo 0%) alanine aminotransferase increased 7.4% (placebo 3.6%) aspartate aminotransferase increased 7.4% (placebo 3.6%) NCT00603512 · Phase 2 · registry result, not featured evidence 1 mg nasopharyngitis 10.7% (placebo 14.3%) headache 7.1% (placebo 3.6%) stomatitis 7.1% (placebo 0%) NCT00603512 · Phase 2 · registry result, not featured evidence 5 mg diarrhoea 12.7% (placebo 3.9%) nasopharyngitis 7% (placebo 5.9%) upper respiratory tract infection 7% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 10 mg cough 8.1% (placebo 0%) influenza 6.8% (placebo 2%) nausea 6.8% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg headache 13.4% (placebo 2%) urinary tract infection 9% (placebo 0%) nasopharyngitis 6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 20 mg to 5 mg (R) headache 23.1% (placebo 2%) upper respiratory tract infection 15.4% (placebo 2%) abdominal pain upper 7.7% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 15 mg nasopharyngitis 8% (placebo 5.9%) alanine aminotransferase increased 6.7% (placebo 2%) aspartate aminotransferase increased 6.7% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg nausea 5.5% (placebo 2%) pharyngitis 5.5% (placebo 3.9%) abdominal pain upper 3.6% (placebo 5.9%) NCT00413660 · Phase 2 · registry result, not featured evidence 3 mg to 5 mg (R) upper respiratory tract infection 23.1% (placebo 2%) arthralgia 15.4% (placebo 0%) headache 15.4% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg diarrhoea 14.3% (placebo 3.9%) abdominal pain upper 4.1% (placebo 5.9%) headache 4.1% (placebo 2%) NCT00413660 · Phase 2 · registry result, not featured evidence 1 mg to 5 mg (R) gastritis 9.5% (placebo 0%) nasopharyngitis 9.5% (placebo 5.9%) oral herpes 9.5% (placebo 0%) NCT00413660 · Phase 2 · registry result, not featured evidence 5 mg BID headache 16.4% (placebo 9.2%) abdominal pain upper 6.6% (placebo 0%) nausea 6.6% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 30 mg BID headache 24.6% (placebo 9.2%) leukopenia 10.1% (placebo 1.5%) nausea 8.7% (placebo 4.6%) NCT00147498 · Phase 2 · registry result, not featured evidence 15 mg BID headache 11.6% (placebo 9.2%) dizziness 5.8% (placebo 1.5%) hypercholesterolaemia 5.8% (placebo 0%) NCT00147498 · Phase 2 · registry result, not featured evidence nasopharyngitis 8.2% (placebo 5.9%) headache 6.2% (placebo 2%) nausea 5.2% (placebo 3.9%) NCT01484561 · Phase 1 · registry result, not featured evidence nausea 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence anemia 16.7% arthralgia 8.3% back pain 8.3% NCT01745055 · Phase 1 · registry result, not featured evidence · combination | 15 mgl upper respiratory tract infection 19.8% (placebo 4.1%) nasopharyngitis 18.5% (placebo 4.1%) urinary tract infection 17% (placebo 3.6%) NCT02675426 · Phase 3 show 48 more results15 mg nausea 6.8% (placebo 3.2%) nasopharyngitis 5.4% (placebo 4.1%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 8.9% (placebo 0%) rheumatoid arthritis 4.5% (placebo 4.5%) fall 2.8% (placebo 0.5%) NCT02675426 · Phase 3 30 mg nasopharyngitis 5.9% (placebo 4.1%) upper respiratory tract infection 5.5% (placebo 4.1%) headache 3.7% (placebo 5.4%) NCT02675426 · Phase 3 30 mg upper respiratory tract infection 17.8% (placebo 4.1%) urinary tract infection 14.3% (placebo 3.6%) nasopharyngitis 14% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 10.5% rheumatoid arthritis 9.4% urinary tract infection 7.2% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 6.3% nasopharyngitis 5.7% nausea 5.7% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 15.5% nasopharyngitis 15.1% urinary tract infection 13.6% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 10.8% upper respiratory tract infection 7.3% urinary tract infection 5.7% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 16.2% nasopharyngitis 16.2% hypertension 14% NCT02706873 · Phase 3 · monotherapy 15 mg QD upper respiratory tract infection 8.6% nasopharyngitis 7.3% urinary tract infection 6.6% NCT03086343 · Phase 3 30 mg QD hypertension 23.5% upper respiratory tract infection 23.5% bronchitis 17.6% NCT03086343 · Phase 3 15 mg urinary tract infection 4.6% upper respiratory tract infection 4.1% blood creatine phosphokinase increased 2.3% NCT02706951 · Phase 3 15 mg nasopharyngitis 17.6% rheumatoid arthritis 14.2% urinary tract infection 13.5% NCT02706951 · Phase 3 30 mg urinary tract infection 4.7% blood creatine phosphokinase increased 4.2% upper respiratory tract infection 2.8% NCT02706951 · Phase 3 30 mg blood creatine phosphokinase increased 18.6% urinary tract infection 15.1% upper respiratory tract infection 14.8% NCT02706951 · Phase 3 15 mg rheumatoid arthritis 9.4% (placebo 5.9%) urinary tract infection 8% (placebo 5.9%) back pain 5.8% (placebo 2.4%) NCT02706847 · Phase 3 15 mg urinary tract infection 9.8% (placebo 5.9%) upper respiratory tract infection 7.9% (placebo 7.7%) bronchitis 4.3% (placebo 2.4%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 31.4% (placebo 7.7%) urinary tract infection 18.2% (placebo 5.9%) nasopharyngitis 14.4% (placebo 6.5%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 6.7% (placebo 7.7%) nasopharyngitis 5.5% (placebo 6.5%) urinary tract infection 5.5% (placebo 5.9%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 27.9% (placebo 7.7%) urinary tract infection 20.4% (placebo 5.9%) nasopharyngitis 17.1% (placebo 6.5%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 20.2% (placebo 6.5%) alanine aminotransferase increased 9.3% (placebo 1.2%) blood creatine phosphokinase increased 9% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 9.5% (placebo 6.5%) alanine aminotransferase increased 5.3% (placebo 1.2%) anaemia 0% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg nasopharyngitis 54.7% (placebo 10.2%) herpes zoster 14.1% (placebo 2%) influenza 14.1% (placebo 4.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 15 mg nasopharyngitis 12.2% (placebo 10.2%) liver function test increased 6.1% (placebo 0%) constipation 4.1% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 43.9% (placebo 10.2%) constipation 15.2% (placebo 0%) herpes zoster 15.2% (placebo 2%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 18% (placebo 10.2%) blood creatine phosphokinase increased 6% (placebo 0%) headache 6% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 53.8% (placebo 10.2%) stomatitis 20% (placebo 6.1%) hypertension 12.3% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 10.2% (placebo 10.2%) hypertension 6.1% (placebo 0%) stomatitis 6.1% (placebo 6.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 12 mg BID/30 mg QD upper respiratory tract infection 20.3% urinary tract infection 15% herpes zoster 11.2% NCT02049138 · Phase 2 · registry result, not featured evidence 6 mg BID/15 mg QD upper respiratory tract infection 9.9% nasopharyngitis 9.5% urinary tract infection 9.5% NCT02049138 · Phase 2 · registry result, not featured evidence 60 mg urinary tract infection 9.8% (placebo 0%) diarrhoea 7.3% (placebo 0%) rheumatoid arthritis 7.3% (placebo 10.5%) NCT03682705 · Phase 2 · registry result, not featured evidence 20 mg rheumatoid arthritis 7.7% (placebo 10.5%) upper respiratory tract infection 7.7% (placebo 5.3%) alopecia 5.1% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 15 mg/60 mg upper respiratory tract infection 6.5% (placebo 5.3%) arthralgia 1.6% (placebo 5.3%) cough 1.6% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence · combination 5 mg rheumatoid arthritis 7.3% (placebo 10.5%) upper respiratory tract infection 4.9% (placebo 5.3%) urinary tract infection 4.9% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 24 mg QD nasopharyngitis 6.1% (placebo 2%) back pain 2% (placebo 0%) blood creatine phosphokinase increased 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID blood creatine phosphokinase increased 4% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 12 mg BID influenza 8% (placebo 0%) nasopharyngitis 8% (placebo 2%) blood creatine phosphokinase increased 6% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 6 mg BID back pain 6% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 3 mg BID headache 4% (placebo 2%) back pain 2% (placebo 0%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID urinary tract infection 12.7% (placebo 3.6%) blood creatine phosphokinase increased 9.1% (placebo 0%) constipation 7.3% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 12 mg BID upper respiratory tract infection 7.3% (placebo 1.8%) headache 5.5% (placebo 1.8%) leukopenia 5.5% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 6 mg BID headache 5.5% (placebo 1.8%) hyperlipidaemia 3.6% (placebo 1.8%) constipation 1.8% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 3 mg BID nausea 7.3% (placebo 1.8%) arthralgia 5.5% (placebo 0%) headache 5.5% (placebo 1.8%) NCT01960855 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dAssessment timepoints differ: 12 weeks versus 312 weeks.
- eAssessment timepoints differ: 12 weeks versus 273 weeks.
- fTrial phases differ: Phase 3 versus Phase 4.
- gTreatment context has not been resolved for both arms.
- hAssessment timepoints differ: 24 weeks versus 104 weeks.
- iTrial phases differ: Phase 3 versus Phase 2.
- jTrial phases differ: Phase 2 versus Phase 3.
- kAssessment timepoints differ: 12 weeks versus 104 weeks.
- lPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tofacitinib
show 35 more results
show 76 more results
show 72 more results
show 76 more results
show 113 more results
show 9 more results
show 203 more results
show 17 more results
show 216 more results
show 96 more results
show 210 more results
show 13 more results
+ 660 further endpoints in the CSV export.
upadacitinib
show 3 more results
show 2 more results
show 18 more results
show 15 more results
show 15 more results
show 3 more results
show 3 more results
Ulcerative Colitis
Shared mechanism: JAK · full Ulcerative Colitis pipeline
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01458951 · Phase 3 · completed
Design meets the 'strong' test: randomized, quadruple-blinded, placebo-controlled, adequately powered (429 vs 112), with a hard clinical/endoscopic composite primary endpoint (Mayo remission including endoscopic subscore) that was statistically significant in the favorable direction (p=0.0005, 13% absolute difference).
Next expected readout: March 2027 · NCT04624230 (registry estimate)
Reported efficacy
Percentage of Participants In Remission at Week 52: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo) (met)
Result source: NCT01458574
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02819635 · Phase 2/3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=1302) trial with a hard clinical/endoscopic composite primary endpoint (Adapted Mayo Score remission, incorporating endoscopy); all primary comparisons across all three substudies and all active doses achieved statistical significance in the favorable direction (p<0.001 to 0.049), satisfying the 'strong' definition.
Next expected readout: March 2027 · NCT07546097 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo) (met)
Result source: NCT03653026
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | tofacitinib | upadacitinib |
|---|---|---|
| Clinical remission (induction) | 16.6% vs 3.6%+13 vs placeboNCT014589512 other results
| 26.1% vs 4.8%+21.3 vs placeboNCT0281963511 other results
|
| Clinical remission (maintenance) | 40.6% vs 11.1%+29.5 vs placeboNCT0145857411 other results
| 51.7% vs 12.1%+39.6 vs placeboNCT028196351 other result
|
| Clinical response (induction) | 55% vs 28.6%+26.4 vs placeboNCT014589511 other result
| 72.6% vs 27.3%+45.3 vs placeboNCT0281963513 other results
|
| Endoscopic improvement (induction) | 28.4% vs 11.6%+16.8 vs placeboNCT014589511 other result
| 36.3% vs 7.4%+28.9 vs placeboNCT028196357 other results
|
| Corticosteroid-free remission (maintenance) | —Trial running · NCT04624230 | —Trial running · NCT06660693 |
Clinical remission (induction)
- tofacitinib
- 16.6% vs 3.6%+13 vs placeboNCT01458951
2 other results
- 16.8% vs 3.6% NCT01458951
- 18.5% vs 8.2% NCT01465763
- upadacitinib
- 26.1% vs 4.8%+21.3 vs placeboNCT02819635
11 other results
- 33.5% vs 4.1% NCT03653026
- 21.4% vs 0% NCT02819635
- 13.5% vs 0% NCT02819635
- 14.3% vs 0% NCT02819635
- 8.5% vs 0% NCT02819635
- 19.6% vs 0% NCT02819635
- 11.5% vs 0% NCT02819635
- 69.7% vs 22.2% NCT02819635
- 10.2% vs 0% NCT02819635
- 59.2% vs 22.2% NCT02819635
- 10.6% vs 0% NCT02819635
Clinical remission (maintenance)
- tofacitinib
- 40.6% vs 11.1%+29.5 vs placeboNCT01458574
11 other results
- 34.3% vs 11.1% NCT01458574
- 41.1% vs 11.1% NCT01458574
- 35.5% vs 11.1% NCT01458574
- 35.5% vs 11.1% NCT01458574
- 34.3% vs 11.1% NCT01458574
- 33.8% vs 11.1% NCT01458574
- 34.3% vs 11.1% NCT01458574
- 56.4% vs 10.2% NCT01458574
- 63.6% vs 15.3% NCT01458574
- 46.2% vs 10.2% NCT01458574
- 55.4% vs 15.3% NCT01458574
- upadacitinib
- 51.7% vs 12.1%+39.6 vs placeboNCT02819635
1 other result
- 42.3% vs 12.1% NCT02819635
Clinical response (induction)
- tofacitinib
- 55% vs 28.6%+26.4 vs placeboNCT01458951
1 other result
- 59.9% vs 32.8% NCT01465763
- upadacitinib
- 72.6% vs 27.3%+45.3 vs placeboNCT02819635
13 other results
- 74.5% vs 25.4% NCT03653026
- 60.1% vs 27.3% NCT02819635
- 63.3% vs 25.9% NCT03653026
- 55.4% vs 13% NCT02819635
- 55.4% vs 17.4% NCT02819635
- 46.2% vs 13% NCT02819635
- 36.5% vs 17.4% NCT02819635
- 76.6% vs 18.8% NCT02819635
- 49% vs 13% NCT02819635
- 34.7% vs 17.4% NCT02819635
- 63% vs 18.8% NCT02819635
- 29.8% vs 13% NCT02819635
- 23.4% vs 17.4% NCT02819635
Endoscopic improvement (induction)
- tofacitinib
- 28.4% vs 11.6%+16.8 vs placeboNCT01458951
1 other result
- 31.3% vs 15.6% NCT01465763
- upadacitinib
- 36.3% vs 7.4%+28.9 vs placeboNCT02819635
7 other results
- 44% vs 8.3% NCT03653026
- 35.7% vs 2.2% NCT02819635
- 26.9% vs 2.2% NCT02819635
- 69.5% vs 19.2% NCT02819635
- 30.6% vs 2.2% NCT02819635
- 61.6% vs 19.2% NCT02819635
- 14.9% vs 2.2% NCT02819635
Corticosteroid-free remission (maintenance)
- tofacitinib
- —Trial running · NCT04624230
- upadacitinib
- —Trial running · NCT06660693
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. tofacitinib: 8 of 8 rows · upadacitinib: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tofacitinib Rows use multiple source trials | upadacitinib |
|---|---|---|
| Endoscopic Improvement responder rate · % of participants Maintenance | 45.7% (n=197) vs 13.1% (n=198) placebo @ 52wk10 mg BIDa,b,c,d NCT01458574 · Phase 3 show 1 more dose37.4% (n=198) vs 13.1% (n=198) placebo @ 52wk5 mg BID NCT01458574 · Phase 3 | 61.6% (n=154) vs 14.5% (n=149) placebo @ 52wk30 mga,b,c,d NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 1 more dose48.7% (n=148) vs 14.5% (n=149) placebo @ 52wk15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 |
| Endoscopic Remission responder rate · % of participants Induction | 7% (n=429) vs 1.8% (n=112) placebo @ 8wk10 mg BIDb,e NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1 other source trial6.7% (n=476) vs 1.6% (n=122) placebo @ 8wk10 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 17.9% (n=56) vs 0% (n=46) placebo @ 8wk45 mga,b,e NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 4 more doses13.7% (n=319) vs 1.3% (n=154) placebo @ 8wk45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 9.6% (n=52) vs 0% (n=46) placebo @ 8wk30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1% (n=49) vs 0% (n=46) placebo @ 8wk15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 6.4% (n=47) vs 0% (n=46) placebo @ 8wk7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 |
| Endoscopic Remission responder rate · % of participants Maintenance | 16.8% (n=197) vs 4% (n=198) placebo @ 52wk10 mg BIDa,b,c,d NCT01458574 · Phase 3 show 1 more dose14.6% (n=198) vs 4% (n=198) placebo @ 52wk5 mg BID NCT01458574 · Phase 3 | 25.9% (n=154) vs 5.6% (n=149) placebo @ 52wk30 mga,b,c,d NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 1 more dose24.2% (n=148) vs 5.6% (n=149) placebo @ 52wk15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 |
| Total Mayo absolute change · score Induction | -3.7 vs -2 placebo score @ 8wk10 mg BIDb,e NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1 other source trial-3.8 vs -1.9 placebo score @ 8wk10 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | -4.606 vs -0.741 placebo score @ 8wk45 mga,b,e NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 3 more doses-4.211 vs -0.741 placebo score @ 8wk30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 -3.589 vs -0.741 placebo score @ 8wk15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 -2.87 vs -0.741 placebo score @ 8wk7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 |
| Dropout rate | 7.5%10 mg BIDf NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 7 more results16.7%15 mg BID NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.5%10 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.3%15 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 36%10 mg BID NCT01458574 · Phase 3 43.9%5 mg BID NCT01458574 · Phase 3 86.5%10 mg BID NCT01470612 · Phase 3 · monotherapy 48%5 mg BID NCT01470612 · Phase 3 · monotherapy | 8.1%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 13 more results12.9%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 10.3%30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 8.2%15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 3.2%45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Discontinued due to AEs | 1.6%10 mg BIDf NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 7 more results0%15 mg BID NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.9%10 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%15 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 4.6%10 mg BID NCT01458574 · Phase 3 2.5%5 mg BID NCT01458574 · Phase 3 10.4%10 mg BID NCT01470612 · Phase 3 · monotherapy 11.4%5 mg BID NCT01470612 · Phase 3 · monotherapy | 3.3%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 13 more results5.8%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 1.9%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 6.1%15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 2.1%7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 1.4%45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Serious AEs | 4.2%10 mg BIDf NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 7 more results0%15 mg BID NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 3.4%10 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%15 mg BID NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6%10 mg BID NCT01458574 · Phase 3 5.1%5 mg BID NCT01458574 · Phase 3 19.1%10 mg BID NCT01470612 · Phase 3 · monotherapy 22.3%5 mg BID NCT01470612 · Phase 3 · monotherapy | 4.9%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 13 more results2.4%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 2.5%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 3.4%45 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 7.9%30 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 —15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 7.4%15 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 0%7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 0%7.5 mg NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 3.2%45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.5%45 mg NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Most frequent reported AEs | 10 mg BIDf headache 7.7% (placebo 8%) anaemia 2.6% (placebo 1.8%) arthralgia 2.6% (placebo 5.4%) NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 7 more results15 mg BID abdominal pain upper 16.7% (placebo 0%) anaemia 16.7% (placebo 1.8%) contusion 16.7% (placebo 0%) NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10 mg BID headache 7.8% (placebo 6.6%) nasopharyngitis 7.1% (placebo 7.4%) nausea 3.2% (placebo 4.1%) NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 15 mg BID acne 18.8% (placebo 0%) nasopharyngitis 18.8% (placebo 7.4%) sinusitis 12.5% (placebo 0.8%) NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10 mg BID colitis ulcerative 14.8% (placebo 32.3%) nasopharyngitis 13.8% (placebo 5.6%) arthralgia 8.7% (placebo 9.6%) NCT01458574 · Phase 3 5 mg BID colitis ulcerative 17.7% (placebo 32.3%) nasopharyngitis 9.6% (placebo 5.6%) arthralgia 8.6% (placebo 9.6%) NCT01458574 · Phase 3 10 mg BID nasopharyngitis 20.4% colitis ulcerative 17% blood creatine phosphokinase increased 11.1% NCT01470612 · Phase 3 · monotherapy 5 mg BID colitis ulcerative 25.1% nasopharyngitis 23.4% influenza 13.1% NCT01470612 · Phase 3 · monotherapy | 45 mg blood creatine phosphokinase increased 6.5% (placebo 0%) headache 6.5% (placebo 10.9%) acne 4.9% (placebo 0%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 show 11 more results45 mg pyrexia 7.1% (placebo 2.2%) anaemia 5.9% (placebo 6.5%) blood creatine phosphokinase increased 5.9% (placebo 0%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 45 mg blood creatine phosphokinase increased 5% (placebo 0%) acne 4.7% (placebo 0%) nasopharyngitis 4.7% (placebo 6.5%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 45 mg blood creatine phosphokinase increased 6.8% (placebo 0%) herpes zoster 5.1% (placebo 0%) abdominal pain 3.4% (placebo 2.2%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 30 mg headache 7.7% (placebo 10.9%) nausea 6.8% (placebo 4.3%) acne 5.1% (placebo 0%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 30 mg nasopharyngitis 9.5% (placebo 6.5%) colitis ulcerative 7.6% (placebo 8.7%) blood creatine phosphokinase increased 6.6% (placebo 0%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 15 mg headache 8.2% (placebo 10.9%) upper respiratory tract infection 8.2% (placebo 0%) anaemia 6.1% (placebo 6.5%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 15 mg colitis ulcerative 12.4% (placebo 8.7%) nasopharyngitis 9.6% (placebo 6.5%) blood creatine phosphokinase increased 6.2% (placebo 0%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 7.5 mg headache 8.5% (placebo 10.9%) abdominal distension 6.4% (placebo 0%) arthralgia 4.3% (placebo 2.2%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 7.5 mg arthralgia 20% (placebo 2.2%) colitis ulcerative 15% (placebo 8.7%) constipation 10% (placebo 2.2%) NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3 45 mg acne 7% (placebo 1.7%) headache 2.3% (placebo 5.1%) anaemia 0% (placebo 0%) NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 45 mg anaemia 5.9% (placebo 0%) blood creatine phosphokinase increased 5.9% (placebo 0%) pyrexia 5.9% (placebo 0%) NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2/3 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation context differs: baseline_threshold differs (adapted_mayo<=9, adapted_mayo>=5 versus none recorded).
- fPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tofacitinib
show 5 more results
show 5 more results
show 5 more results
show 3 more results
show 5 more results
show 7 more results
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
upadacitinib
show 5 more results
show 3 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: JAK · full Psoriatic Arthritis pipeline
tofacitinib · Xeljanz
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03104400 · Phase 3 · completed
This was a large randomized, double-blind trial with both a placebo and an adalimumab arm. A power calculation planned about 1,640 patients and 1,705 were enrolled, and both upadacitinib doses met the primary endpoint against placebo, ACR20 response at week 12 (70.6% and 78.5% vs 36.2%, p<0.0001).
Next expected readout: September 2028 · NCT06454188 (registry estimate)
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) (met)
Result source: NCT03104400
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | tofacitinib | upadacitinib |
|---|---|---|
| ACR20 | 50.5% vs 33.3%+17.1 vs placeboNCT0187766827 other results
| 70.6% vs 36.2%+34.4 vs placeboNCT0310440011 other results
|
| ACR50 | 28.0% vs 9.5%+18.5 vs placeboNCT0187766827 other results
| 37.5% vs 13.2%+24.3 vs placeboNCT031044003 other results
|
| PASI 75 | 42.7% vs 14.6%+28.1 vs placeboNCT0187766815 other results
| 62.6% vs 21.3%+41.3 vs placeboNCT031044003 other results
|
| Minimal disease activity | —Not reported | 36.6% vs 12.3%+24.3 vs placeboNCT031044003 other results
|
| HAQ-DI, change | -0.3 vs -0.2−0.2 vs placeboNCT0187766827 other results
| -0.4 vs -0.1−0.3 vs placeboNCT031044005 other results
|
ACR20
- tofacitinib
- 50.5% vs 33.3%+17.1 vs placeboNCT01877668
27 other results
- 49.6% vs 23.7% NCT01882439
- 60.6% vs 33.3% NCT01877668
- 47.0% vs 23.7% NCT01882439
- 43.9% vs 26.7% NCT01877668
- 48.1% vs 25.9% NCT01882439
- 34.6% vs 10.5% NCT01877668
- 34.4% vs 22.1% NCT01882439
- 22.4% vs 5.7% NCT01877668
- 26.7% vs 13.0% NCT01882439
- 54.8% vs 26.7% NCT01877668
- 47.7% vs 25.9% NCT01882439
- 48.1% vs 10.5% NCT01877668
- 42.4% vs 22.1% NCT01882439
- 31.7% vs 5.7% NCT01877668
- 28.8% vs 13.0% NCT01882439
- 60.8% vs 57.5% NCT01877668
- 59.5% NCT01882439
- 58.9% vs 64.2% NCT01877668
- 59.5% NCT01882439
- 68.2% vs 68.9% NCT01877668
- 68.2% vs 60.4% NCT01877668
- 57.7% vs 57.5% NCT01877668
- 52.3% NCT01882439
- 67.3% vs 64.2% NCT01877668
- 49.2% NCT01882439
- 73.1% vs 68.9% NCT01877668
- 70.2% vs 60.4% NCT01877668
- upadacitinib
- 70.6% vs 36.2%+34.4 vs placeboNCT03104400
11 other results
- 56.9% vs 24.1% NCT03104374
- 78.5% vs 36.2% NCT03104400
- 63.8% vs 24.1% NCT03104374
- 70.6% vs 36.2% NCT03104400
- 70.6% vs 36.2% NCT03104400
- 28.2% vs 12.1% NCT03104400
- 32.7% vs 10.8% NCT03104374
- 78.5% vs 36.2% NCT03104400
- 78.5% vs 36.2% NCT03104400
- 38.3% vs 12.1% NCT03104400
- 33.5% vs 10.8% NCT03104374
ACR50
- tofacitinib
- 28.0% vs 9.5%+18.5 vs placeboNCT01877668
27 other results
- 29.8% vs 14.5% NCT01882439
- 21.5% vs 7.6% NCT01877668
- 25.2% vs 10.7% NCT01882439
- 12.2% vs 4.8% NCT01877668
- 17.6% vs 6.1% NCT01882439
- 6.5% vs 0.9% NCT01877668
- 6.1% vs 3.0% NCT01882439
- 40.4% vs 9.5% NCT01877668
- 28.0% vs 14.5% NCT01882439
- 32.7% vs 7.6% NCT01877668
- 22.7% vs 10.7% NCT01882439
- 19.2% vs 4.8% NCT01877668
- 10.6% vs 6.1% NCT01882439
- 6.7% vs 0.9% NCT01877668
- 9.8% vs 3.0% NCT01882439
- 44.9% vs 40.6% NCT01877668
- 42.1% vs 46.2% NCT01877668
- 38.3% vs 42.5% NCT01877668
- 38.2% NCT01882439
- 35.5% vs 32.1% NCT01877668
- 38.2% NCT01882439
- 48.1% vs 40.6% NCT01877668
- 46.1% vs 46.2% NCT01877668
- 46.1% vs 42.5% NCT01877668
- 29.6% NCT01882439
- 37.5% vs 32.1% NCT01877668
- 28.8% NCT01882439
- upadacitinib
- 37.5% vs 13.2%+24.3 vs placeboNCT03104400
3 other results
- 31.8% vs 4.7% NCT03104374
- 51.8% vs 13.2% NCT03104400
- 37.6% vs 4.7% NCT03104374
PASI 75
- tofacitinib
- 42.7% vs 14.6%+28.1 vs placeboNCT01877668
15 other results
- 21.3% vs 13.9% NCT01882439
- 23.2% vs 4.9% NCT01877668
- 15% vs 5.8% NCT01882439
- 44.3% vs 14.6% NCT01877668
- 43.2% vs 13.9% NCT01882439
- 27.1% vs 4.9% NCT01877668
- 18.5% vs 5.8% NCT01882439
- 56.1% vs 55.8% NCT01877668
- 43.9% vs 58.4% NCT01877668
- 46.3% vs 54.5% NCT01877668
- 33.8% NCT01882439
- 67.1% vs 55.8% NCT01877668
- 68.6% vs 58.4% NCT01877668
- 60% vs 54.5% NCT01877668
- 45.7% NCT01882439
- upadacitinib
- 62.6% vs 21.3%+41.3 vs placeboNCT03104400
3 other results
- 52.3% vs 16% NCT03104374
- 62.4% vs 21.3% NCT03104400
- 56.5% vs 16% NCT03104374
Minimal disease activity
- tofacitinib
- —Not reported
- upadacitinib
- 36.6% vs 12.3%+24.3 vs placeboNCT03104400
3 other results
- 25.1% vs 2.8% NCT03104374
- 45.4% vs 12.3% NCT03104400
- 28.9% vs 2.8% NCT03104374
HAQ-DI, change
- tofacitinib
- -0.3 vs -0.2−0.2 vs placeboNCT01877668
27 other results
- -0.4 vs -0.1 NCT01882439
- -0.4 vs -0.2 NCT01877668
- -0.4 vs -0.1 NCT01882439
- -0.3 vs -0.2 NCT01877668
- -0.4 vs -0.2 NCT01882439
- -0.2 vs -0.1 NCT01877668
- -0.3 vs -0.1 NCT01882439
- -0.2 vs -0.1 NCT01877668
- -0.2 vs -0.1 NCT01882439
- -0.4 vs -0.2 NCT01877668
- -0.3 vs -0.2 NCT01882439
- -0.3 vs -0.1 NCT01877668
- -0.2 vs -0.1 NCT01882439
- -0.2 vs -0.1 NCT01877668
- -0.2 vs -0.1 NCT01882439
- -0.4 vs -0.4 NCT01877668
- -0.4 NCT01882439
- -0.4 vs -0.4 NCT01877668
- -0.4 NCT01882439
- -0.5 vs -0.4 NCT01877668
- -0.5 vs -0.4 NCT01877668
- -0.4 vs -0.4 NCT01877668
- -0.3 NCT01882439
- -0.5 vs -0.4 NCT01877668
- -0.3 NCT01882439
- -0.5 vs -0.4 NCT01877668
- -0.5 vs -0.4 NCT01877668
- upadacitinib
- -0.4 vs -0.1−0.3 vs placeboNCT03104400
5 other results
- -0.4 vs -0.1 NCT03104400
- -0.3 vs -0.1 NCT03104374
- -0.5 vs -0.1 NCT03104400
- -0.5 vs -0.1 NCT03104400
- -0.4 vs -0.1 NCT03104374
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. tofacitinib: 8 of 8 rows · upadacitinib: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tofacitinib | upadacitinib |
|---|---|---|
| ACR70 responder rate · % of participants | 23.36% (n=107) vs NA placebo @ 52wk5 mg twice dailya,b,c,d NCT01877668 · Phase 3 show 1 more dose30.77% (n=104) vs NA placebo @ 52wk10 mg twice daily NCT01877668 · Phase 3 | 15.6% (n=429) vs 2.4% (n=423) placebo @ 12wk15 mga,b,c,d NCT03104400 · Phase 3 show 1 more dose25.3% (n=423) vs 2.4% (n=423) placebo @ 12wk30 mg NCT03104400 · Phase 3 |
| FACIT-Fatigue absolute change · score | 8.5 vs NA placebo score @ 52wk5 mg twice dailya,b,c,d NCT01877668 · Phase 3 show 1 more dose8.4 vs NA placebo score @ 52wk10 mg twice daily NCT01877668 · Phase 3 | 6.3 vs 2.8 placebo score @ 12wk15 mga,b,c,d NCT03104400 · Phase 3 show 1 more dose7.1 vs 2.8 placebo score @ 12wk30 mg NCT03104400 · Phase 3 |
| Modified Sharp absolute change · score | 0.01 vs -0.07 Adalimumab score @ 48wk5 mg twice dailya,b,c,e NCT01877668 · Phase 3 show 1 more dose-0.01 vs -0.07 Adalimumab score @ 48wk10 mg twice daily NCT01877668 · Phase 3 | -0.04 vs 0.25 placebo score @ 24wk15 mga,b,c,e NCT03104400 · Phase 3 show 1 more dose0.03 vs 0.25 placebo score @ 24wk30 mg NCT03104400 · Phase 3 |
| SF-36 PCS absolute change · score | 7.61 vs NA placebo score @ 52wk5 mg twice dailya,b,c,d NCT01877668 · Phase 3 show 1 more dose7.67 vs NA placebo score @ 52wk10 mg twice daily NCT01877668 · Phase 3 | 7.86 vs 3.19 placebo score @ 12wk15 mga,b,c,d NCT03104400 · Phase 3 show 1 more dose8.9 vs 3.19 placebo score @ 12wk30 mg NCT03104400 · Phase 3 |
| Dropout rate | 10.3%5 mg twice dailyf NCT01877668 · Phase 3 show 11 more results7.7%10 mg twice daily NCT01877668 · Phase 3 6.9%5 mg Twice Daily NCT01882439 · Phase 3 15.9%10 mg, Twice Daily NCT01882439 · Phase 3 5.1%Tofacitinib NCT03486457 · Phase 3 · registry result, not featured evidence —Tofacitinib: Up to Month 3 NCT03486457 · Phase 3 · registry result, not featured evidence —Tofacitinib: Up to Month 6 NCT03486457 · Phase 3 · registry result, not featured evidence —5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence —5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence · combination 32.2%Tofacitinib NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy 14.9%5 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence 31.3%10 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence | 11.9%15 mgf NCT03104400 · Phase 3 show 12 more results—15 mg NCT03104400 · Phase 3 —15 mg NCT03104400 · Phase 3 13.5%30 mg NCT03104400 · Phase 3 —30 mg / 15 mg NCT03104400 · Phase 3 —30 mg NCT03104400 · Phase 3 —30 mg NCT03104400 · Phase 3 —15 mg NCT03104374 · Phase 3 —15 mg NCT03104374 · Phase 3 20.9%15 mg NCT03104374 · Phase 3 —30 mg NCT03104374 · Phase 3 —30 mg NCT03104374 · Phase 3 24.2%30 mg NCT03104374 · Phase 3 |
| Discontinued due to AEs | 5.6%5 mg twice dailyf NCT01877668 · Phase 3 show 11 more results2.9%10 mg twice daily NCT01877668 · Phase 3 3.8%5 mg Twice Daily NCT01882439 · Phase 3 7.6%10 mg, Twice Daily NCT01882439 · Phase 3 1.5%Tofacitinib NCT03486457 · Phase 3 · registry result, not featured evidence —Tofacitinib: Up to Month 3 NCT03486457 · Phase 3 · registry result, not featured evidence —Tofacitinib: Up to Month 6 NCT03486457 · Phase 3 · registry result, not featured evidence —5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence —5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence · combination 9.2%Tofacitinib NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy 8.5%5 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence 8.3%10 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence | 2.1%15 mgf NCT03104400 · Phase 3 show 12 more results—15 mg NCT03104400 · Phase 3 —15 mg NCT03104400 · Phase 3 5%30 mg NCT03104400 · Phase 3 —30 mg / 15 mg NCT03104400 · Phase 3 —30 mg NCT03104400 · Phase 3 —30 mg NCT03104400 · Phase 3 —15 mg NCT03104374 · Phase 3 —15 mg NCT03104374 · Phase 3 5.7%15 mg NCT03104374 · Phase 3 —30 mg NCT03104374 · Phase 3 —30 mg NCT03104374 · Phase 3 6.4%30 mg NCT03104374 · Phase 3 |
| Serious AEs | 7.5%5 mg twice dailyf NCT01877668 · Phase 3 show 11 more results3.8%10 mg twice daily NCT01877668 · Phase 3 3.8%5 mg Twice Daily NCT01882439 · Phase 3 6.1%10 mg, Twice Daily NCT01882439 · Phase 3 —Tofacitinib NCT03486457 · Phase 3 · registry result, not featured evidence 0%Tofacitinib: Up to Month 3 NCT03486457 · Phase 3 · registry result, not featured evidence 1.5%Tofacitinib: Up to Month 6 NCT03486457 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence 3.4%5 mg BID NCT01976364 · Phase 3 · registry result, not featured evidence · combination —Tofacitinib NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy 6.4%5 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence 6.4%10 mg BID NCT01519089 · Phase 3 · registry result, not featured evidence | —15 mgf NCT03104400 · Phase 3 show 12 more results6.5%15 mg NCT03104400 · Phase 3 28.8%15 mg NCT03104400 · Phase 3 —30 mg NCT03104400 · Phase 3 12.4%30 mg / 15 mg NCT03104400 · Phase 3 10.9%30 mg NCT03104400 · Phase 3 18%30 mg NCT03104400 · Phase 3 10.4%15 mg NCT03104374 · Phase 3 14.4%15 mg NCT03104374 · Phase 3 —15 mg NCT03104374 · Phase 3 11.4%30 mg NCT03104374 · Phase 3 11.5%30 mg NCT03104374 · Phase 3 —30 mg NCT03104374 · Phase 3 |
| Most frequent reported AEs | 5 mg twice dailyf upper respiratory tract infection 9.3% nasopharyngitis 7.5% blood creatine phosphokinase increased 4.7% NCT01877668 · Phase 3 show 9 more results10 mg twice daily nasopharyngitis 11.5% headache 10.6% upper respiratory tract infection 10.6% NCT01877668 · Phase 3 5 mg Twice Daily nasopharyngitis 10.7% upper respiratory tract infection 9.2% diarrhoea 7.6% NCT01882439 · Phase 3 upper respiratory tract infection 18.4% (placebo 10.3%) abdominal discomfort 6.6% (placebo 1.5%) blood creatine phosphokinase increased 6.6% (placebo 1.5%) NCT03486457 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 26.5% (placebo 10.3%) blood creatine phosphokinase increased 14.7% (placebo 1.5%) hyperlipidaemia 10.3% (placebo 2.9%) NCT03486457 · Phase 3 · registry result, not featured evidence 5 mg BID upper respiratory tract infection 4.4% urinary tract infection 4.4% bronchitis 3.3% NCT01976364 · Phase 3 · registry result, not featured evidence 5 mg BID upper respiratory tract infection 6.7% pharyngitis 3.4% psoriatic arthropathy 3.4% NCT01976364 · Phase 3 · registry result, not featured evidence · combination 5 mg BID nasopharyngitis 29.8% psoriasis 8.5% tinea pedis 8.5% NCT01519089 · Phase 3 · registry result, not featured evidence 10 mg BID nasopharyngitis 29.8% herpes zoster 21.3% psoriasis 12.8% NCT01519089 · Phase 3 · registry result, not featured evidence | 15 mgf upper respiratory tract infection 15.6% (placebo 8%) blood creatine phosphokinase increased 12.1% (placebo 1.4%) nasopharyngitis 8.4% (placebo 5%) NCT03104400 · Phase 3 show 8 more results15 mg covid-19 34.9% (placebo 0%) upper respiratory tract infection 14.8% (placebo 8%) blood creatine phosphokinase increased 11.4% (placebo 1.4%) NCT03104400 · Phase 3 30 mg / 15 mg covid-19 26.4% (placebo 0%) upper respiratory tract infection 11.1% (placebo 8%) blood creatine phosphokinase increased 8.8% (placebo 1.4%) NCT03104400 · Phase 3 30 mg upper respiratory tract infection 17% (placebo 8%) blood creatine phosphokinase increased 15.8% (placebo 1.4%) nasopharyngitis 10.6% (placebo 5%) NCT03104400 · Phase 3 30 mg covid-19 13.9% (placebo 0%) upper respiratory tract infection 10.9% (placebo 8%) blood creatine phosphokinase increased 9% (placebo 1.4%) NCT03104400 · Phase 3 15 mg nasopharyngitis 11.4% (placebo 8%) upper respiratory tract infection 10.4% (placebo 4.7%) urinary tract infection 9% (placebo 5.7%) NCT03104374 · Phase 3 15 mg covid-19 12.6% (placebo 0%) hypertension 11.4% (placebo 4.7%) urinary tract infection 10.2% (placebo 5.7%) NCT03104374 · Phase 3 30 mg nasopharyngitis 13.2% (placebo 8%) upper respiratory tract infection 13.2% (placebo 4.7%) blood creatine phosphokinase increased 10% (placebo 1.9%) NCT03104374 · Phase 3 30 mg psoriatic arthropathy 9.7% (placebo 5.2%) urinary tract infection 8.5% (placebo 5.7%) herpes zoster 7.9% (placebo 0.9%) NCT03104374 · Phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 52 weeks.
- eAssessment timepoints differ: 24 weeks versus 48 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tofacitinib
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 27 more results
show 15 more results
show 9 more results
show 15 more results
show 15 more results
+ 95 further endpoints in the CSV export.
upadacitinib
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tofacitinib's landscape · upadacitinib's landscape